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ABSTRACT OF THE DISSERTATION
Mechanisms of Brain Region-Specific Amyloid-β Deposition
by
Adam William Bero
Doctor of Philosophy in Neurosciences
Washington University in St. Louis, 2011
David M. Holtzman, M.D., Chairperson

Alzheimer’s disease (AD) is the most common cause of dementia. A fundamental
feature of AD is brain region-specific deposition of extracellular amyloid plaques
principally comprised of the amyloid-β (Aβ) peptide. Using mouse models of cerebral
Aβ deposition, we examined molecular, cellular and systems-level mechanisms that
regulate brain region-specific Aβ accumulation and aggregation. Parallel studies using in
vivo multiphoton microscopy and in vivo microdialysis revealed that modest
pharmacological reduction of soluble interstitial fluid (ISF) Aβ levels was associated with
a dramatic reduction in amyloid plaque formation and growth. We found that ISF Aβ
concentrations in several brain regions of APP transgenic mice prior to the onset of
plaque deposition were proportional to the degree of subsequent plaque deposition and
with the concentration of lactate, a marker of neuronal activity. Moreover, we found that
physiological modulation of endogenous neuronal activity by vibrissal manipulation was
sufficient to modulate ISF Aβ levels and amyloid plaque growth dynamics. Using a
ii

novel optical intrinsic signal imaging approach, we found that bilateral functional
connectivity magnitude in APP/PS1 mice prior to plaque deposition was proportional to
the amount of regional plaque deposition in aged APP/PS1 mice. Furthermore, we found
that bilateral functional connectivity was reduced in normal aging and was markedly
exacerbated by Aβ deposition. Together, these data suggest that endogenous neuronal
activity and functional connectivity may regulate region-specific Aβ plaque deposition.
These data advance our understanding of the mechanisms by which the intrinsic
metabolic and functional organization of the brain may contribute to AD pathogenesis.
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Chapter 1.
Introduction and perspective
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Alzheimer’s disease
Alzheimer’s disease (AD) is the most common cause of dementia. It is estimated
that over 26 million individuals worldwide suffer from AD, including over 10% of
individuals ≥ 65 years of age and nearly 50% of individuals ≥ 85 years of age (Thies and
Bleiler, 2011). Given that no treatment that halts or reverses the progression of AD is
available, and that the number of AD cases and associated costs are projected to
quadruple by the year 2050, a greater understanding of the molecular mechanisms of AD
pathogenesis is urgently needed.
Short-term memory dysfunction is an early and essential feature of cognitive
decline in AD. At initial clinical presentation, short-term memory dysfunction is
typically accompanied by deficits in executive function, attention and problem-solving.
As the disease progresses into successive stages of severity, changes such as personality
alteration, language dysfunction and a reduced capacity to perform activities of daily
living gradually emerge. Following the onset of clinical symptoms, the time course of
AD dementia averages 7-10 years and culminates uniformly in death.
The first reported case of AD was described by Alois Alzheimer at the 37th
Conference of South-West German Psychiatrists in Tübingen, Germany in November of
1906. There, Alzheimer described his clinicopathological evaluation of Auguste Deter, a
patient who presented with a ―peculiar‖ dementia at 51 years of age. Upon her death at
age 55, Alzheimer utilized the Bielschowsky silver impregnation technique to visualize
―miliary foci‖ and ―striking changes of the neurofibrils‖ throughout Deter’s cerebral
cortex (Alzheimer et al., 1995). These pathologies, later described as amyloid plaques
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and neurofibrillary tangles, respectively, constitute the principle neuropathological
hallmarks of AD.
Amyloid-β peptide and amyloid plaque deposition
Several decades after Alois Alzheimer’s initial description, cerebrovascular
amyloid deposits and intraparenchymal extracellular amyloid plaques isolated from AD
brain were discovered to be principally composed of aggregated forms of the amyloid-β
(Aβ) peptide (Glenner & Wong, 1984; Masters et al., 1985). Aβ is a 38-43 amino acid
peptide of unknown function that is derived from normal metabolism of amyloid
precursor protein [APP; (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992)].
APP is a type I transmembrane protein that is predominantly expressed in neurons in the
central nervous system and is sequentially cleaved by two proteases, β-secretase (Vassar
et al., 1999) and γ-secretase (De Strooper et al., 1998), to generate Aβ. Alternative APP
cleavage by the α-secretase protease occurs within the Aβ sequence and thus precludes
Aβ generation (Lammich et al., 1999). Intramembranous γ-secretase cleavage of APP at
various amino acid residues at the C-terminus of the Aβ sequence produces Aβ peptides
of varying amino acid length and aggregation propensity. Of these, Aβ1-40 is the most
abundant Aβ species in the brain and cerebrospinal fluid. Present at only 5-10% of the
concentration of Aβ1-40, Aβ1-42 is nonetheless regarded as the primary pathogenic Aβ
species as it is more hydrophobic and thus more likely to self-aggregate and seed amyloid
plaque deposition (Hasegawa et al., 1999; Kim et al., 2007). Under normal conditions,
Aβ is released by neurons in a soluble form and can be measured in the plasma and
cerebrospinal fluid of cognitively normal individuals throughout life (Fagan et al., 2006).
During AD pathogenesis, soluble Aβ aggregates into higher-order species such as soluble
3

oligomers and insoluble amyloid plaques in a concentration-dependent manner (MeyerLuehmann et al., 2003). Amyloid plaque deposition in AD is associated with myriad
types of neurotoxicity, including neuritic dystrophy (Brendza et al., 2005; MeyerLuehmann et al., 2008), disrupted brain metabolism (Klunk et al., 2004; Sperling et al.,
2009), decreased functional connectivity (Supekar et al., 2008; Hedden et al., 2009;
Sheline et al., 2010a; Drzezga et al., 2011), neuroinflammation (Bolmont et al., 2008;
Meyer-Luehmann et al., 2008), neurofibrillary tangle formation (Bolmont et al., 2007),
and synaptic and neuronal loss (Jack et al., 2009).
In the years since the identification of Aβ as the primary constituent of amyloid
plaques in AD brain, genetic, biochemical and neurobiological evidence has mounted to
suggest that Aβ accumulation and aggregation initiate a pathogenic cascade of molecular
events that ultimately culminate in symptomatic AD (Selkoe, 2000; Hardy and Selkoe,
2002). ―Sporadic‖, ―late-onset‖ (age > 60 years) AD (LOAD) accounts for ~99% of
symptomatic AD cases. Of the several genes in which mutations have been reported to
modulate susceptibility to LOAD, the apolipoprotein E (APOE) ε4 allele confers the
greatest risk and decreases average age of dementia onset by 10-20 years (Corder et al.,
1993; Saunders et al., 1993). In contrast, the APOE ε2 allele confers protection and
reduces risk of LOAD development (West et al., 1994). Consistent with the amyloid
cascade hypothesis, CSF and amyloid imaging data suggest that cognitively normal
middle-aged to elderly APOE ε4 carriers exhibit lower CSF Aβ1-42 levels, greater brain
amyloid deposition and reduced brain glucose metabolism relative to noncarriers
(Reiman et al., 1996; Sunderland et al., 2004; Reiman et al., 2009; Morris et al., 2010).
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In a small percentage (~1%) of AD cases (familial AD, FAD), the disease is
inherited in a fully-penetrant, autosomal dominant manner and dementia typically
manifests between 30 and 60 years of age. Missense mutations in the coding sequence of
APP were the first mutations identified to segregate with FAD or CAA (Levy et al.,
1990; Van Broeckhoven et al., 1990; Goate et al., 1991). Since then, several mutations in
APP, PSEN1 and PSEN2 have been found to result in FAD (Holtzman et al., 2011).
Importantly, all identified FAD-linked mutations either increase total Aβ levels, Aβ42
levels or increase Aβ aggregation propensity (Holtzman et al., 2011).
Using positron emission tomography (PET), amyloid deposition in human brain
can be directly assessed in vivo through systemic infusion of a radiolabeled compound
that readily crosses the blood-brain barrier and binds specifically to amyloid plaques
(Klunk et al., 2004). Amyloid deposition in human brain can also be indirectly assessed
through analysis of Aβ1-42 levels in cerebrospinal fluid (CSF); CSF Aβ1-42 concentration
is significantly reduced in AD and likely reflects sequestration of soluble Aβ into
parenchymal plaques (Fagan et al., 2006). Furthermore, biomarkers such as high CSF
tau/Aβ42 and elevated brain amyloid deposition are predictive of conversion from
cognitive normalcy to very mild dementia (Fagan et al., 2007; Morris et al., 2009; CraigSchapiro et al., 2010) and from mild cognitive impairment to AD (Hansson et al., 2006).
As cerebral amyloid plaque deposition begins 10-15 years prior to the onset of clinical
symptoms (Perrin et al., 2009), preclinical detection of amyloid pathology using
physiological fluid and neuroimaging biomarkers will likely represent a critical
component of future AD diagnosis, treatment and prevention.
Mouse models of Aβ plaque deposition
5

Identification of mutations that result in FAD has greatly facilitated generation of
AD mouse models. Though existing mouse models do not recapitulate the full
complement of pathology present in human AD brain (Ashe and Zahs, 2010), they have
provided valuable insights into specific components of AD pathogenesis.
Transgenic overexpression of human APP containing one or more FAD-linked
mutations is sufficient to induce age-related Aβ plaque deposition in mouse brain. One
such mouse model, Tg2576 (APPswe), expresses the 695 amino acid form of human APP
containing the K670N/M671L FAD mutation under the transcriptional regulation of the
hamster prion protein promoter (Hsiao et al., 1996). In Tg2576 mice, transgenic APP
expression in neurons and astrocytes is approximately 5.5 fold greater than expression of
endogenous murine APP. Parenchymal Aβ1-40 and Aβ1-42 levels are increased by ~5 and
14-fold, respectively (Hsiao et al., 1996; Kawarabayashi et al., 2001). Aβ plaque
deposition begins between 9-10 months of age and is associated with the onset of
learning and memory deficits (Hsiao et al., 1996). Importantly, Aβ plaque deposition in
Tg2576 mouse brain exhibits regional specificity similar to that observed in human AD
brain. Therefore, the Tg2576 mouse model represents a useful tool with which to
examine the cellular and molecular mechanisms underlying brain region-specific Aβ
plaque deposition.
Though mutations in PSEN1 account for the majority of FAD cases (Holtzman et
al., 2011), transgenic overexpression of human PSEN1 containing FAD-linked mutations
does not induce Aβ plaque deposition in mouse brain. However, coexpression of mutant
human PSEN1 and APP transgenes in bitransgenic mice can hasten the onset and rate of
cerebral Aβ plaque deposition relative to singly transgenic APP mutant mice (Borchelt et
6

al., 1997; Holcomb et al., 1998; Lamb et al., 1999; Jankowsky et al., 2004). Accordingly,
Aβ plaque deposition begins between 4-5 months of age in APPswe/PS1ΔE9 (APP/PS1)
bitransgenic mice. The degree of acceleration of Aβ plaque deposition is proportional to
the increase in the Aβ 42:40 ratio induced by mutant PSEN1 (Jankowsky et al., 2004).
Though the mechanisms are unclear, regional differences in Aβ plaque deposition are less
robust in APP/PS1 compared to Tg2576 mice.
Neuronal activity and ISF Aβ metabolism
Following its intracellular generation, Aβ is secreted into the extracellular fluid of
the brain in soluble form (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992).
Given that amyloid plaques are extracellular structures, and that Aβ aggregation is
concentration-dependent (Hasegawa et al., 1999; Meyer-Luehmann et al., 2003), the
concentration of soluble Aβ within the brain extracellular fluid is hypothesized to
represent a key determinant of whether and when Aβ will aggregate in vivo. Therefore,
several reports have sought to elucidate the mechanisms that regulate Aβ release into the
brain extracellular fluid. In 1992, two reports demonstrated that pharmacological
activation of cell-surface M1 or M3 muscarinic acetylcholine receptor subtypes increased
release of APP derivatives in cell culture (Buxbaum et al., 1992; Nitsch et al., 1992). In
the following year, these findings were extended by the demonstration that electrical
depolarization of rat hippocampal slices increased release of APP derivatives and that
electrical stimulation-induced APP derivative release was prevented by the addition of
tetrodotoxin, a voltage-gated sodium channel blocker (Nitsch et al., 1993). Using APP
transgenic mice and rat organotypic hippocampal slices infected with human APP,
Kamenetz and colleagues later showed that a pharmacological increase of neuronal
7

activity by picrotoxin, a GABAA receptor antagonist, increased Aβ generation and
secretion while a decrease in neuronal activity by tetrodotoxin decreased Aβ generation
and secretion (Kamenetz et al., 2003). However, the role of neuronal activity in Aβ
formation and secretion in vivo remained unknown.
To test the hypothesis that neuronal activity directly regulates Aβ secretion into
the extracellular fluid in vivo, Cirrito and colleagues in our laboratory utilized a novel Aβ
microdialysis technique (Cirrito et al., 2003) to sample Aβ concentration in the brain
interstitial fluid (ISF) of awake, behaving mice while performing electrical or
pharmacological manipulation of neuronal activity (Cirrito et al., 2005). Consistent with
findings showing that APP is axonally transported from entorhinal cortex to hippocampus
via the perforant pathway (Buxbaum et al., 1998), and that perforant pathway lesions
reduce hippocampal Aβ plaque deposition in APP transgenic mice (Lazarov et al., 2002;
Sheng et al., 2002), Cirrito and colleagues found that acute electrical stimulation of the
perforant pathway increased ISF Aβ levels in hippocampus of APP transgenic mice
within minutes (Cirrito et al., 2005). Moreover, they found that hippocampal infusion of
tetrodotoxin via reverse microdialysis reversibly reduced ISF Aβ and EEG amplitude and
that pharmacological inhibition of synaptic vesicle exocytosis via tetanus toxin reduced
ISF Aβ levels. Finally, they used organotypic hippocampal slice culture to show that
stimulation of synaptic vesicle exocytosis increased ISF Aβ levels in the absence of
action potentials, suggesting that synaptic activity directly regulates ISF Aβ concentration
in vivo (Cirrito et al., 2005). Consistent with in vitro reports showing that cell-surface
APP is internalized by clathrin-mediated endocytosis (Nordstedt et al., 1993) and that
APP is cleaved by β-secretase and γ-secretase within early and late endosomes to produce
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Aβ (Vassar et al., 1999; Lah and Levey, 2000), the majority (~70%) of synaptic Aβ
secretion in vivo was later demonstrated to require clathrin-mediated endocytosis (Cirrito
et al., 2008).
Recent reports from our laboratory have demonstrated that certain behavioral and
environmental manipulations regulate ISF Aβ levels at least in part through modulation
of neuronal activity. For instance, acute and chronic restraint stress increase hippocampal
ISF Aβ levels in APP transgenic mice and stress-induced increases in ISF Aβ levels are
prevented by local infusion of tetrodotoxin (Kang et al., 2007). Consistent with previous
reports suggesting that wakefulness is associated with increased cerebral glucose
utilization and synaptic potentiation compared to sleep (Vyazovskiy et al., 2008b;
Vyazovskiy et al., 2008a; Gilestro et al., 2009), our laboratory has also demonstrated that
hippocampal ISF Aβ levels exhibit diurnal fluctuation in both APP transgenic and wildtype mice (Kang et al., 2009). Moreover, acute sleep deprivation increases ISF Aβ levels
in hippocampus while chronic sleep deprivation exacerbates Aβ plaque deposition (Kang
et al., 2009). However, whether physiological neuronal activity regulates ISF Aβ levels
remains unclear.
Default-mode network and Aβ deposition
Much of the knowledge gained from human neuroimaging comes from
experiments in which a task-induced change in neural activation is measured relative to a
resting-state control condition. Using this approach, one can visualize localized stimulusinduced changes in brain activation and thus relate brain topography to function (Petersen
et al., 1988; Buckner et al., 1999). However, given that the resting human brain
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consumes 20% of the body’s energy and that task-related increases in brain activation are
minor (< 5%) relative to resting brain metabolism, most of the knowledge gained from
human neuroimaging comes from examination of a small fraction of total brain activity.
Indeed, an early study of cerebral energy metabolism found no significant change in
global brain metabolism during performance of a challenging arithmetic problem relative
to a quiet resting state (Sokoloff et al., 1955).
In cognitively normal adults, it is now well-established that a specific set of brain
regions, including medial prefrontal, lateral parietal, posterior cingulate/retrosplenial
cortices, is preferentially activated during undirected mentation and is deactivated during
task performance. As activity in this neural network is most robust in the absence of a
task, this subset of brain regions was termed the ―default-mode network‖ (Raichle et al.,
2001; Raichle and Mintun, 2006; Raichle and Snyder, 2007). Activity in the defaultmode network is typically ascribed to self-referential thinking, autobiographical memory
retrieval and planning for future events (Buckner et al., 2008). Importantly, as restingstate brain metabolism accounts for the majority of total brain metabolism, default-mode
network activity is hypothesized to account for the majority of total brain activity.
A fundamental feature of AD is the deposition of extracellular Aβ plaques in
specific brain regions. However, the mechanism by which specific brain regions are
rendered vulnerable to Aβ plaque deposition in AD remains unknown. To begin to
address this issue, Randy Buckner and colleagues used functional magnetic resonance
imaging (fMRI) to show that the distribution of resting-state brain metabolism in
cognitively normal young adults is closely associated with the topology of amyloid
plaque deposition in AD (Buckner et al., 2005). This discovery was recently extended by
10

data suggesting that the distribution of resting-state aerobic glycolysis (defined as glucose
utilization in excess of that used for oxidative phosphorylation despite sufficient oxygen
to completely metabolize glucose to carbon dioxide and water) in cognitively normal
adult brain is region-specific (Vaishnavi et al., 2010) and that the distribution of restingstate aerobic glycolysis in cognitively normal adults exhibits a strong spatial correlation
with amyloid plaque deposition in AD (Vlassenko et al., 2010). However, despite
evidence of a close spatial relationship between brain energy metabolism and Aβ
deposition in human brain, the mechanisms by which specific brain regions are rendered
vulnerable to Aβ plaque deposition in AD remain unknown. Given the near
proportionality between neuronal energy consumption and neurotransmitter cycling in
vivo (Hyder et al., 2006), and given that evidence from our laboratory and others suggests
that neuronal activity directly regulates ISF Aβ levels in vitro and in vivo (Kamenetz et
al., 2003; Cirrito et al., 2005; Cirrito et al., 2008), one possibility is that regional
differences in resting-state neuronal activity regulate the regional specificity of Aβ plaque
deposition through long-term modulation of ISF Aβ concentration.
Functional connectivity and Aβ deposition
In 1995, Biswal and colleagues observed that spontaneous fluctuations in the
resting-state BOLD signal measured in left sensorimotor cortex of cognitively normal
adults were correlated in time specifically with spontaneous fluctuations in right
sensorimotor cortex (Biswal et al., 1995). Such temporal coherence of neural activity in
spatially distinct brain regions, termed ―functional connectivity‖, is now recognized as an
intrinsic component of normal brain metabolism (Fox and Raichle, 2007).
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Recent large-scale resting-state functional connectivity MRI (fcMRI) and diffuse
spectrum imaging data suggest that certain areas of human brain contain
disproportionately high levels of functional and structural connectivity (Hagmann et al.,
2008; Buckner et al., 2009). Intriguingly, several of these cortical ―hubs‖ are located in
regions of the default-mode network. Given that brain regions that comprise the defaultmode network are those most susceptible to amyloid plaque deposition in AD, there
exists a striking spatial correspondence between areas of elevated resting-state functional
connectivity in cognitively normal brain and the pattern of amyloid plaque deposition in
AD (Buckner et al., 2009). Moreover, recent reports have demonstrated that functional
connectivity within the default-mode network is disrupted in AD (Supekar et al., 2008;
Zhang et al., 2009), cognitively normal adults who harbor significant brain amyloid
plaque deposition (Hedden et al., 2009; Drzezga et al., 2011) and in normal aging
(Andrews-Hanna et al., 2007).
Examination of the relationships between functional connectivity, Aβ plaque
deposition and normal aging would be greatly facilitated by the ability to measure
systems-level functional connectivity in genetically and pharmacologically tractable
model systems. However, given that the small size of mouse brain requires an
exceptionally high signal-to-noise ratio to sufficiently resolve region-specific BOLD
signal fluctuations, the relationship between functional connectivity, amyloid plaque
deposition and normal aging remains unknown.
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Chapter 2.
Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice

13

PREFACE
The work in this chapter was published in the August 26, 2009 issue of The Journal of
Neuroscience. Adam W. Bero and Ping Yan (laboratory of Jin-Moo Lee) contributed
equally to this work.
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ABSTRACT
Amyloid plaques are primarily composed of extracellular aggregates of amyloid-β (Aβ)
peptide and are a pathological signature of Alzheimer's disease. However, the factors that
influence the dynamics of amyloid plaque formation and growth in vivo are largely
unknown. Using serial intravital multiphoton microscopy through a thinned-skull cranial
window in APP/PS1 transgenic mice, we found that amyloid plaques appear and grow
over a period of weeks before reaching a mature size. Growth was more prominent early
after initial plaque formation: plaques grew faster in 6-month-old compared with 10month-old mice. Plaque growth rate was also size-related, as smaller plaques exhibited
more rapid growth relative to larger plaques. Alterations in interstitial Aβ concentrations
were associated with changes in plaque growth. Parallel studies using multiphoton
microscopy and in vivo microdialysis revealed that pharmacological reduction of soluble
extracellular Aβ by as little as 20–25% was associated with a dramatic decrease in plaque
formation and growth. Furthermore, this small reduction in Aβ synthesis was sufficient to
reduce amyloid plaque load in 6-month-old but not 10-month-old mice, suggesting that
treatment early in disease pathogenesis may be more effective than later treatment. In
contrast to thinned-skull windows, no significant plaque growth was observed under
open-skull windows, which demonstrated extensive microglial and astrocytic activation.
Together, these findings indicate that individual amyloid plaque growth in vivo occurs
over a period of weeks and may be influenced by interstitial Aβ concentration as well as
reactive gliosis.
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INTRODUCTION
Amyloid-β (Aβ) is a 38-43 amino acid peptide that is produced in neurons by the
sequential proteolytic cleavage of the amyloid precursor protein (APP) by β-secretase and
γ-secretase (Selkoe, 2001). Under normal conditions, Aβ is secreted into the extracellular
space [interstitial fluid (ISF)] of the brain, where it is found in soluble form throughout
life (Cirrito et al., 2003). Aggregation of Aβ into compact amyloid plaques is associated
with local neuritic dystrophy (Knowles et al., 1999; D'Amore et al., 2003; Lombardo et
al., 2003; Brendza et al., 2005; Garcia-Alloza et al., 2006; Meyer-Luehmann et al., 2008),
neuronal and astrocytic calcium dysregulation (Busche et al., 2008; Kuchibhotla et al.,
2008; Kuchibhotla et al., 2009) and disruption of cortical synaptic integration (Stern et
al., 2004) and is widely considered to represent a necessary factor in Alzheimer's disease
(AD) pathogenesis (Hardy and Selkoe, 2002). In vitro studies of Aβ aggregation kinetics
demonstrate that Aβ monomers polymerize to form higher order aggregates in a
concentration-dependent manner (Burdick et al., 1992). Although similar aggregation
steps are believed to occur during plaque pathogenesis in the AD brain, the dynamics of
this process in vivo are not well understood. Since amyloid deposits are primarily present
in the extracellular space of the brain, the concentration of soluble Aβ in the ISF is likely
a key determinant of Aβ aggregation. This hypothesis is supported by transplantation
studies in which wild-type neural grafts in APP transgenic hosts developed amyloidosis,
suggesting that host-derived soluble Aβ diffused through the ISF and seeded amyloid
formation in the graft (Meyer-Luehmann et al., 2003). However, a direct relationship
between soluble, extracellular Aβ and amyloid plaque growth dynamics in vivo has not
been demonstrated.
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Since β-secretase and γ-secretase activity is necessary for Aβ generation, drug discovery
efforts have aimed to inhibit these enzymes to halt or reverse the progression of amyloid
pathology in AD. However, γ-secretase is also required for the proteolysis of a multitude
of other type 1 transmembrane proteins including Notch (De Strooper et al., 1999),
ErbB4 (Ni et al., 2001) and CD44 (Lammich et al., 2002). Thus, complete inhibition of
this enzyme is associated with significant mechanism-based toxicity, including atrophy of
the thymus and altered intestinal cell differentiation (Wong et al., 2004). Interestingly,
genetic reduction of γ-secretase activity throughout life by as little as 30% is sufficient to
attenuate amyloid pathology in a mouse model of AD while limiting toxicity (Li et al.,
2007). However, it is not known whether, and to what extent, transient pharmacological
reduction of extracellular Aβ is associated with altered amyloid plaque growth dynamics
in adult animals.
Given the overwhelming evidence that Aβ accumulation is necessary for AD
pathogenesis, it is critical to understand the mechanisms that govern Aβ plaque formation
and growth in vivo. To this end, we used serial in vivo multiphoton microscopy to
monitor the growth of individual plaques over time and in vivo microdialysis to
determine the relationship between ISF Aβ concentration and amyloid plaque growth in
APPswe/PS1ΔE9 (APP/PS1) transgenic mice.
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MATERIALS AND METHODS
Animals.
Male and female APPswe/PS1ΔE9 mice (Jankowsky et al., 2004; Savonenko et al.,
2005); APP/PS1; The Jackson Laboratory) were aged to 6 ± 0.5 or 10 ± 0.5 months for
multiphoton microscopy experiments and 3 ± 0.5 months for in vivo microdialysis
experiments. All experimental protocols were approved by the Animal Studies
Committee at Washington University.
Open-skull cranial window surgery.
Open-skull cranial windows were prepared on the day of the first imaging session as
previously described (Bolmont et al., 2008; Meyer-Luehmann et al., 2008). Briefly, mice
were anesthetized under volatile isoflurane (2% induction, 1.5% maintenance), and the
skin and periosteum were removed to expose the skull. Lines forming a square (6 mm)
were drilled into the skull surface using a high-speed drill (Fine Science Tools), and a
pair of angled forceps was used to remove the circumscribed region of skull without
damaging the dura mater. A glass coverslip (8 mm in diameter) was placed over the
open-skull region and was sealed to the skull with dental cement. A 2-mm-high wall of
dental cement was constructed around the coverslip to create a water-immersion chamber
for subsequent imaging (supplemental Fig. 1A).
Thinned-skull cranial window surgery.
Thinned-skull cranial windows were prepared on the day of the first imaging session as
previously described (Christie et al., 2001; Tsai et al., 2004). Briefly, mice were
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anesthetized (as described above), and the skin and periosteum were removed to expose
the skull. A high-speed drill and microsurgical blade (Surgistar) were used to thin the
skull until the skull window was transparent and displayed flexibility. Pial vasculature
was clearly visualized through the window and served as a guide to repeatedly locate the
same sites in the brain at subsequent imaging sessions (supplemental Fig. 1B). Two
thinned-skull windows (each 0.8–1.0 mm in diameter) were prepared on each animal.
Multiphoton microscopy.
To examine plaque growth, individual plaques were observed longitudinally. Twentyfour hours before each imaging session, animals were injected intraperitoneally with
methoxy-X04 (5 mg/ml in 10% DMSO, 45% propylene glycol, and 45% saline), a
fluorescent compound that crosses the blood–brain barrier and binds to amyloid plaques
(Klunk et al., 2002). The animal was anesthetized and mounted on a custom-built
stereotaxic apparatus (Brendza et al., 2005). For thinned-skull window preparations, a
small ring of molten bone wax was applied to the skull surrounding the perimeter of the
window to create a chamber for water immersion. The skull window was placed directly
under the objective lens on a two-photon microscope [LSM 510 META NLO system
(Carl Zeiss Inc.) with a Chameleon Ti: Sapphire laser (Coherent Inc.)]. To image
methoxy-X04-labeled plaques, two-photon fluorescence was generated with 750 nm
excitation, and fluorescent emission was detected in the range of 435–485 nm. A 10×
water-immersion objective [numerical aperture (NA) = 0.33, Zeiss] was used to create a
site map during initial imaging and a 40× water-immersion objective (NA = 0.75, Zeiss)
was used for detailed analysis of individual plaques. A z-stack image series was acquired
from the skull surface to a depth of ∼200 μm into cortex. Incremental z-step distance was
19

10 μm under the 10× objective and 5 μm under the 40× objective. At the conclusion of
each imaging session, the animal was removed from the stage and the scalp was sutured.
To examine plaque growth over time, the same sites for each animal were imaged on day
0 and day 7, 28, or 90. To determine whether laser intensity might impact plaque size
determination, a visual field containing multiple plaques was repeatedly imaged using
increasing laser power (14–20%) while detection gain and amplification parameters were
held constant (supplemental Fig. 2A,B). No significant differences were found between
the different laser intensities.
Image analysis.
Collapsed z-stack images for each individual plaque were measured by cross-sectional
area and intensity using SigmaScan Pro Image Analysis Software (Systat Software) with
a preset threshold (threshold = mean + 4 * SD) (supplemental Fig. 2C,D). Plaques were
excluded from analysis if they were located on the edge of the thinned-skull window, if
they exhibited a fluorescence intensity less than the mean intensity of an adjacent
background region, or if the images were affected by motion artifacts (from heartbeat or
respiration).
Double immunofluorescence.
To compare microglial and astrocytic activation in cortex under open- and thinned-skull
window preparations, animals were transcardially perfused with 0.9% saline followed by
4% paraformaldehyde in 0.01 M PBS immediately after the second multiphoton imaging
session. Brains were removed and postfixed in 4% paraformaldehyde for an additional 4
h. Coronal free-floating sections (50 μm) were cut on a cryostat. Sections were incubated
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overnight at 4°C in a combination of rabbit anti-Iba1 (1:1000; Wako Chemicals) and
mouse anti-GFAP monoclonal antibody (1:1000; Sigma). A secondary antibody mixture
of Cy3-conjugated

donkey anti-rabbit

IgG

(1:800;

Jackson

ImmunoResearch

Laboratories) and Alexa Fluor 488-conjugated donkey anti-mouse IgG (1:400;
Invitrogen) was applied. Sections were washed, mounted, and examined using a confocal
microscope (Zeiss LSM).
Compound E treatment.
To examine the effect of reduced Aβ concentration on plaque growth dynamics, mice
were treated with either vehicle or the potent γ-secretase inhibitor, Compound E (3
mg/kg; Axxora) daily for 7 or 28 d (Grimwood et al., 2005). To examine the effect of
Compound E on ISF Aβ levels, mice were treated with either a single dose of 3 mg/kg
Compound E (i.p.) or treated daily with vehicle or 3 mg/kg Compound E for 7 d.
Amyloid plaque load quantification.
To determine the effect of Compound E treatment on overall cortical amyloid plaque
load, 6- and 10-month-old animals were treated with vehicle or Compound E (3 mg/kg,
i.p.) daily for 28 d. Mice were subsequently transcardially perfused with 0.9% saline
followed by 4% paraformaldehyde in 0.01 M PBS. Brains were dissected, fixed with 4%
paraformaldehyde, cryosectioned (50-μm-thick slices), and stained with 100 μM X-34 in
staining buffer (40% ethanol/60% PBS, pH 10) for 20 min and differentiated with
staining buffer three times, each, for 2 min to visualize compact plaques (Styren et al.,
2000). Cortical plaque load was expressed as percentage of cortical area covered by X34-positive staining.
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In vivo microdialysis.
In vivo microdialysis used to measure Aβ in the brain ISF of awake, freely behaving mice
was performed as previously described (Cirrito et al., 2003; Cirrito et al., 2005; Kang et
al., 2007; Cirrito et al., 2008). One day before drug treatment, guide cannulae (BR-style,
Bioanalytical Systems) were stereotaxically implanted into the left barrel cortex (at
bregma, 2.0 mm lateral to midline, and 1.0 mm below the dura mater at a 32° angle) of
APP/PS1 mice under isoflurane volatile anesthesia. After guide cannula implantation, a 2
mm microdialysis probe [BR-2, 38 kDa MWCO (molecular weight cutoff membrane),
Bioanalytical Systems] was inserted through the guide cannula so the microdialysis
membrane was contained entirely within the barrel cortex. Mice were allowed to recover
from anesthesia and were housed in a Raturn Cage system (Bioanalytical Systems) with
ad libitum access to food and water for the remainder of the experiment. The
microdialysis probe was connected to a syringe pump (Stoelting Co.) and artificial CSF
(aCSF), containing (in mM) 1.3 CaCl2, 1.2 MgSO4, 3 KCl, 0.4 KH2PO4, 25 NaHCO3, and
122 NaCl, pH 7.35, was continuously perfused through the microdialysis probe at a
constant flow rate of 0.7 μl/min. Artificial CSF contained 0.15% bovine serum albumin
to limit nonspecific loss of Aβ. Dialysis samples were collected using a refrigerated
fraction collector (SciPro Inc.) into polypropylene tubes for subsequent measurements of
Aβ1-x, Aβx-40, or Aβx-42 by ELISA, as described below. Mice were treated
intraperitoneally with either a single dose of Compound E (3 mg/kg) or daily with vehicle
or Compound E (3 mg/kg) for 7 d. In single-dose experiments, baseline levels of ISF Aβ
were defined as the mean concentration of Aβ 8 h before drug treatment. Because
artifactual fluctuations in ISF Aβ levels are occasionally observed 3–4 d after insertion of
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the microdialysis probe (our unpublished observations), we chose to monitor ISF Aβ
levels during days 5, 6, and 7 of treatment in multiple-dose experiments. Based on our
finding that ISF Aβ levels collected 16–24 h after a single dose of Compound E did not
differ from pretreatment baseline levels, baseline levels of ISF Aβ in multiple-dose
experiments were defined as the mean concentration of Aβ from hours 16–24 after each
injection of Compound E. After each experiment, animals were killed.
Aβ ELISA assay.
Microdialysis samples were analyzed for Aβ1-x, Aβx-40, or Aβx-42 using species-specific
sandwich ELISAs. Briefly, Aβ1-x, Aβx-40, and Aβx-42 were captured using monoclonal
antibodies targeted against amino acids 13-28 (m266), 35-40 (HJ2), or 33-42 (21F12) of
Aβ, respectively. The antibodies m266, 21F12, and 3D6 were gifts from Eli Lilly. For
Aβ1-x assays, a biotinylated N-terminal domain monoclonal antibody (3D6B) followed by
streptavidin-poly-HRP-20 was used to detect (Fitzgerald). For Aβx-40 and Aβx-42 assays, a
biotinylated central domain monoclonal antibody (HJ5.1B) followed by streptavidinpoly-HRP-40 was used to detect (Fitzgerald). All assays were developed using Super
Slow ELISA TMB (Sigma) and read on a Bio-Tek FL-600 plate reader at 650 nm.
Statistical analysis.
Longitudinal changes in cross-sectional area of individual plaques were analyzed using
paired t tests. Differences in average fold increase of amyloid plaques at multiple time
points as a function of imaging interval were analyzed using a one-way ANOVA
followed by Dunn's post hoc test. To assess differences in individual plaque growth as a
function of drug treatment, the fold increase of mean plaque size was analyzed using a
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paired t test (SigmaStat statistical software v 2.0, Systat Software). Group differences in
percentage area covered by X-34-positive staining were analyzed by Student's t tests. In
microdialysis experiments, time point comparisons of ISF Aβ levels were performed
using one- and two-way ANOVAs followed by Bonferroni post hoc t tests. Differences in
mean ISF Aβ levels between groups were compared using a paired t test (GraphPad
Prism v 4.0). All data in figures represent mean ± SEM. In all tests, the level of
significance was set at p ≤ 0.05.
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RESULTS
Amyloid plaques exhibit age- and size-related growth under thinned-skull windows
Using serial intravital multiphoton microscopy, individual amyloid plaques were imaged
through thinned-skull cranial windows over 7, 28, and 90 d intervals in 6- and 10-monthold APP/PS1 transgenic mice. In 6-month-old mice, plaque size increased significantly
over 7, 28, and 90 d intervals (Figs. 1, 2A–C; supplemental Fig. 4A,C). Over a 7 d
interval, 21% of plaques grew by at least twofold, with a maximum of fourfold growth
(Fig. 2A; supplemental Fig. 4A). Over a 28 d interval, 62% of plaques increased by
twofold or more, with a maximum of sixfold growth (Fig. 2B; supplemental Fig. 4A,C).
Notably, the average fold increase in plaque size over a 90 d period was no greater than
that observed over the 28 d period, suggesting that plaques adopted a stable size before
these two imaging time points (Fig. 2C,D; supplemental Fig. 4A). Although the net effect
of plaque dynamics indicated average plaque growth, there was a great deal of variability.
Indeed, many plaques remained stable during the observed time intervals and rare
examples of plaque regression were also evident (supplemental Fig. 4B). In contrast to
plaque growth observed in 6-month-old animals, plaques imaged in 10-month-old mice
did not exhibit significant growth over 7 or 90 d periods (Fig. 2D). Plaque growth was
also related to plaque size, as smaller plaques exhibited a greater growth rate compared
with larger plaques regardless of animal age (Fig. 2E). Consistent with these findings,
plaques sampled in 6-month-old mice exhibited a smaller mean size than 10-month-old
mice and showed greater mean growth (supplemental Fig. 3C). Moreover, newly formed
plaques were significantly smaller than preexisting plaques (supplemental Fig. 3D). Thus,
individual amyloid plaque growth in vivo is related to animal age and plaque size.
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Open-skull cranial window preparations do not show plaque growth and are
associated with extensive gliosis
In contrast to the robust plaque growth observed under thinned-skull window
preparations, plaques imaged in 6-month-old APP/PS1 mice under open-skull cranial
window preparations did not exhibit significant growth but did show some evidence of
regression over a 28 d interval (Fig. 2F; supplemental Fig. 4C). These findings are
consistent with two recent two-photon studies using open-skull windows (Bolmont et al.,
2008; Meyer-Luehmann et al., 2008). Technical differences between the two window
types are shown in supplemental Figure 1, and include open (craniotomy)- versus closedskull preparations, size differences (6 mm diameter in open-skull vs <0.8 mm in closedskull windows), and the presence of a foreign body (coverslip) in open-skull windows
versus none in closed-skull windows. To examine functional consequences of the
different cranial window types, we performed a comparative analysis of microglial and
astrocytic activation under thinned- and open-skull window preparations. Seven days
after open-skull surgery, extensive microglial activation (Iba-1 immunostain, Fig. 3A)
was present in cortex under the open-skull window, whereas activated microglia were
largely absent in the contralateral control hemisphere. Astrocytic activation (GFAP
immunostain, Fig. 3B) was also abundant in cortex under the open-skull window but rare
in contralateral control cortex. Even at low power, extensive immunostaining is visible in
the region immediately below the cranial window. In contrast, microglial and astrocytic
activation occurred only immediately surrounding plaques under thinned-skull window
preparations and was indistinguishable from the respective contralateral control
hemispheres (Fig. 3C,D). These results indicate that open-skull, but not thinned-skull,
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window preparations are associated with extensive cortical gliosis and suggest that
reactive glial activation may underlie the suppressed plaque growth dynamics observed
under open-skull window preparations. Our findings are consistent with those of Dr. W.
G. Bao, who has reported increased gliosis under open-skull windows associated with
altered dynamics in synaptic spine behavior (Xu et al., 2007). Thus, for the remaining
multiphoton studies, all experiments were performed using thinned-skull windows.
γ-Secretase inhibition suppresses plaque growth and new plaque appearance in vivo
To assess the effects of reduced Aβ production on longitudinal growth of individual
plaques, we measured plaque growth in 6- and 10-month-old APP/PS1 mice treated with
either the potent γ-secretase inhibitor, Compound E (3 mg/kg), or vehicle daily for 7 or
28 d (n = 4/group). Compound E suppressed plaque growth in 6-month-old mice over 7
and 28 d intervals (Fig. 4). Treatment for 28 d in 6-month-old animals also dramatically
attenuated the appearance of new plaques: 0.4390 ± 0.1391 new plaques per mm 3 in
vehicle-treated versus 0.0506 ± 0.0339 in Compound E-treated mice (Student's t test, *p
≤ 0.05). In contrast, plaques imaged in 10-month-old mice did not exhibit significant
growth over the 7 or 90 d interval regardless of drug treatment (supplemental Fig. 5).
Importantly, although Compound E treatment was sufficient to dramatically decrease
plaque growth, it did not induce regression in average plaque size.
To determine whether suppressed growth of individual plaques was reflective of changes
in overall plaque burden, 6- and 10-month-old APP/PS1 mice were treated with
Compound E (3 mg/kg) or vehicle daily for 28 d (n = 8/group); mice were killed, brains
were sectioned and immunostained, and compact plaque load was determined.
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Compound E reduced X-34-positive cortical plaque burden by 23% in 6-month-old mice
compared with vehicle-treated controls (Fig. 5). No difference was detected in 10-monthold mice, similar to findings recently reported (Garcia-Alloza et al., 2009). These results
indicate that modest γ-secretase inhibition was sufficient to decrease amyloid plaque load
and size when administered during the plaque growth phase and suggest that longitudinal
growth of individual amyloid plaques is a fundamental mechanism by which plaque load
increases in AD. Of note, individual plaque growth measured by multiphoton microscopy
(n = 4) is a much more sensitive measure than average grouped plaque burden measures
(n = 8).
Modest reduction in ISF Aβ concentration is associated with a dramatic reduction
in amyloid plaque growth in vivo
We next performed in vivo microdialysis experiments to determine the extent to which
this dose of Compound E affects ISF Aβ concentrations. Three-month-old APP/PS1 mice
were treated with a single dose of Compound E (3 mg/kg) while cortical in vivo
microdialysis was performed to directly measure ISF Aβ levels in living mice.
Compound E treatment decreased ISF Aβ1-x by 27% during the first 8 h after treatment
and had no effect during the remaining 16 h of sample collection (n = 6; supplemental
Fig. 6A,B). To determine the effect of 7 d treatment with Compound E on ISF Aβ, we
treated 3-month-old APP/PS1 mice with Compound E (3 mg/kg) or vehicle for 7 d and
performed microdialysis during the final 3 d of drug treatment. Compound E treatment
decreased ISF Aβx-40 and Aβx-42 levels by 41% (n = 4/group) and 44% (n = 4/group),
respectively, during the first 8 h after injection compared with controls (Fig. 6A,B). Aβx-40
and Aβx-42 levels exhibited more modest reductions during hours 8–16 after Compound E
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treatment and were no different from controls during the final 8 h after injection (Fig.
6A,B). Expressed as relative levels over a 24 h period, Compound E reduced ISF Aβx-40
levels by 22% (n = 4/group) and Aβx-42 by 25% (n = 4/group) compared with controls
(Fig. 6C). Together, these results suggest that a modest decrease in ISF Aβ levels may be
sufficient to arrest amyloid plaque growth in vivo.
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DISCUSSION
Amyloid plaques, primarily composed of aggregated Aβ, exist in the extracellular space
of the brain and are a pathological hallmark of AD. However, the factors that govern the
formation and growth of plaques in the living brain are unknown. In the present study, we
used serial in vivo multiphoton microscopy in APP/PS1 mice to directly quantify amyloid
plaque formation and growth in vivo. We found that although many plaques remained
stable in size at both ages examined, plaques imaged in 6-month-old APP/PS1 mice
exhibited robust growth relative to plaques found in 10-month-old mice, suggesting that
plaque growth is more prominent early in disease pathogenesis. This finding is consistent
with reports of biphasic development of plaque load in APP transgenic mice; compact
plaque load is reported to increase with age (Sturchler-Pierrat et al., 1997; Wengenack et
al., 2000; Jack et al., 2005; Braakman et al., 2006; Harigaya et al., 2006) before
stabilizing at later disease stages (Gordon et al., 2002). Plaque load stabilization has also
been hypothesized to occur in human AD patients, as amyloid burden does not correlate
with disease duration (Hyman et al., 1993; Engler et al., 2006) and plaque burden in a
subset of patients with mild cognitive impairment is indistinguishable from AD patients
(Lopresti et al., 2005; Price et al., 2005; Mintun et al., 2006). Our study also indicated
that plaque growth was related to plaque size, as smaller plaques exhibited greater rates
of growth compared with larger plaques, regardless of age.
We also found that treatment with the γ-secretase inhibitor, Compound E, markedly
decreased the appearance of new plaques and growth of preexisting plaques in APP/PS1
mice. This suppression in plaque appearance and growth was reflected in a decrease in
total plaque burden in parallel cross-sectional studies. To determine the extent to which
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Compound E treatment reduced soluble extracellular Aβ levels in vivo, we used in vivo
microdialysis to measure ISF Aβ levels in APP/PS1 mice treated with Compound E.
Chronic dosing of Compound E over a 7 d period decreased ISF Aβx-40 and Aβx-42 levels
by only 20–25% over a 24 h period. That reduced extracellular Aβ concentration is
associated with inhibition of amyloid plaque growth but not plaque regression is
consistent with previous data obtained using transgenic mice that overexpress mutant
APP under the regulation of a tetracycline-responsive promoter. Inhibition of mutant APP
expression for 6 months after plaque formation arrested the progression of amyloid
pathology but did not reduce overall plaque burden (Jankowsky et al., 2005). A more
recent report demonstrated that 3 weeks of treatment with an orally active γ-secretase
inhibitor did not reduce size of existing plaques in APP/PS1 mice (Garcia-Alloza et al.,
2009). Together, these studies suggest that a kinetic disequilibrium between Aβ plaque
aggregation and dissociation may exist in vivo.
The hypothesis that soluble extracellular Aβ concentration is a key determinant of Aβ
aggregation in vivo is supported by data demonstrating that areas of the brain that
ultimately develop plaque pathology have higher basal ISF Aβ levels early in life relative
to brain regions that do not develop pathology (Cirrito et al., 2003). Moreover,
intracerebral injection of Aβ-containing brain extract from human AD patients or APP
transgenic mice induces cerebral amyloidosis in APP transgenic mice in a concentrationdependent manner (Meyer-Luehmann et al., 2003). Although correlative, the present
study is the first demonstration of the relationship between soluble ISF Aβ and amyloid
plaque growth in vivo. Moreover, it is the first report that this relationship can be
modulated with pharmacological intervention. That a modest reduction of ISF Aβ levels
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is associated with inhibition of amyloid plaque growth and attenuation of new plaque
formation is consistent with recent data demonstrating that a 30% reduction in γ-secretase
activity, as seen with knocking out γ-secretase components throughout life, can attenuate
plaque burden in a mouse model of AD (Li et al., 2007). Thus, partial γ-secretase
inhibition may be sufficient to arrest amyloid plaque progression in AD.
A number of potential therapeutic implications follow from the results of the present
study. First, the observation that γ-secretase inhibition can prevent growth of existing
plaques and attenuate new plaque formation, but not induce plaque regression suggests
that anti-Aβ treatments may be most efficacious if administered early in disease
pathogenesis. This hypothesis is supported by our cross-sectional study, showing that 28
d Compound E treatment reduced amyloid plaque load in 6-month-old APP/PS1 mice,
but not in 10-month-old mice. Moreover, our finding that a modest reduction in soluble,
extracellular Aβ is associated with a dramatic reduction in plaque growth and formation
may have important implications for drug dosing and pharmacodynamic effects of antiAβ therapeutics to be used in clinical trials.
Our present observations of individual plaque growth over a period of weeks are in
contrast to a recent report which showed that plaques reach a mature size within 24 h
after appearance (Meyer-Luehmann et al., 2008). We hypothesized that these differences
might be due to different techniques used to create transcranial windows. We used a
small (<0.8 mm diameter) closed thinned-skull window in our experiments, in contrast to
the larger (6 mm diameter) open-skull (craniotomy) window used by Meyer-Luehmann et
al. (2008) (see supplemental Fig. 1A,B). A direct comparison of plaque growth using
these two techniques revealed robust growth under thinned-skull window preparations,
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but no significant growth under open-skull preparations. In addition, the open-skull
preparation was associated with extensive cortical microglial and astrocytic activation,
which was largely absent under the thinned-skull window. These findings are consistent
with a previous comparison of these two techniques, which demonstrated that the openskull window resulted in significant reactive gliosis and an alteration of dendritic spine
dynamics compared with the closed thinned-skull window (Xu et al., 2007). Coupled
with previous reports implicating reactive gliosis in plaque size maintenance and
regression (Gordon et al., 2002; Wyss-Coray et al., 2003; El Khoury et al., 2007; Takata
et al., 2007; Bolmont et al., 2008), this may explain the discrepancy between the findings
using the two different techniques.
In summary, our results suggest that individual amyloid plaques grow over a period of
weeks and that the rate of plaque growth is related to disease stage, plaque size, gliosis,
and soluble extracellular Aβ concentration. Thus, growth of individual plaques may be a
fundamental mechanism by which plaque load increases in AD. Furthermore, the present
results suggest that a decrease in ISF Aβ levels by as little as 20–25% at key time points
in plaque development may be sufficient to prevent the progression of amyloid
pathology.
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Figure 1. Serial in vivo multiphoton microscopy demonstrates growth of individual
amyloid plaques. (A, B) Epifluorescence micrographs of 4 plaques labeled with
methoxy-X04 and imaged over a 7-day interval in the brain of a 6 month-old APP/PS1
mouse. (C, D) Multiphoton micrographs of those same 4 plaques illustrate growth of
individual plaques over time. Scale bars: 20μm.
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Figure 2. Amyloid plaques exhibit age- and size-related growth under thinned-skull
window preparations. Using serial intravital multiphoton microscopy, individual
plaques were labeled with methoxy-X04 and imaged at multiple time points. Plaque
growth was expressed as fold-increase in cross-sectional area relative to initial plaque
size. (A-C) In 6 month-old APP/PS1 mice, plaques exhibited significant growth over 7-,
28- and 90-day intervals (Paired t-test, *=p≤0.05). (D) Time course of plaque growth in 6
and 10 month-old mice. In 6 month-old animals, the average fold-increase in plaque size
over a 28-day period was significantly greater than that observed over a 7-day period.
There was no difference between average fold-increase over a 28-day period compared to
that over a 90-day period (one-way ANOVA followed by Dunn's post-hoc test,
*=p≤0.05). Plaques imaged in 10 month-old animals did not exhibit significant plaque
growth at either the 7- or 90-day interval (Paired t-test). (E) Average plaque growth is
plotted as a function of initial plaque size. Regardless of animal age, smaller plaques
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grew at a greater rate compared to larger plaques. (F) Plaques imaged in 6 month-old
animals under open-skull window preparations did not exhibit significant growth over a
28-day interval.
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Figure 3. Open-skull cranial window preparations are associated with extensive
gliosis. (A) Low-magnification image of Iba-1 immunofluorescence (red) illustrates
extensive microglial activation in cortex under the open-skull cranial window but not in
contralateral control cortex. High-power micrographs colabeled for methoxy-X04positive plaques (blue) reveal little microglial activation in control hemisphere (A1), but
robust microglial activation under the open-skull window (A2). (B) Low magnification
image of GFAP immunofluorescence (green) demonstrates extensive activation of
astrocytes in cortex under the open-skull cranial window. High-power micrographs
illustrate astrocytic activation only in the immediate vicinity of plaques in control cortex
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(B1), while robust astrocytic activation is present throughout cortex under the open-skull
window (B2). (C) Iba-1-positive microglia are not abundantly visible at lowmagnification under a thinned-skull cranial window preparation. High-power
micrographs illustrate rare microglial activation in control cortex (C1) and under the
thinned-skull window (C2). (D) Astrocytic activation is not robust at low-magnification
under a thinned-skull window preparation. Astrocytic activation is rare in control cortex
(D1) and under the thinned-skull window (D2). Scale bars: A-D, 200 μm; A1-D2, 50 μm.

38

Figure 4. γ-secretase inhibition suppresses plaque growth and new plaque
formation. (A, B) Representative multiphoton micrographs of plaques imaged at a 28day interval in a vehicle-treated 6 month-old APP/PS1 mouse illustrate growth of existing
plaques (arrows) and appearance of new plaques (arrow heads). (C, D) Plaque growth
was suppressed in mice treated with the γ-secretase inhibitor, Compound E (3 mg/kg,
i.p). All images are collapsed z-stack images (100-120 μm thick). (E) Plaques imaged in
vehicle-treated mice exhibited significant growth over 7- and 28-day intervals, while
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plaque growth was attenuated in Compound E-treated mice. (n=4 mice/group; Student's ttest, * p≤0.05). The dotted line indicates no growth, and scale bars = 20 μm.
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Figure 5. γ-secretase inhibition reduces plaque load in 6 month-old APP/PS1 mice.
Six and 10 month-old APP/PS1 mice were treated daily with Compound E (3 mg/kg, i.p.)
or vehicle for 28 days. Compound E reduced X-34-positive cortical plaque load by 23%
in 6 month-old animals compared to vehicle-treated controls. No difference was present
between groups in 10 month-old animals (n=8 mice/group; Student's t-test, *=p≤0.05).
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Figure 6. γ-secretase inhibition results in modest decreases in ISF Aβ levels in
cortex. Three month-old APP/PS1 mice were treated daily with Compound E (3 mg/kg,
i.p.) or vehicle for 7 days. In vivo microdialysis was performed to measure ISF Aβx-40 and
Aβx-42 in cortex throughout the final 3 days of drug treatment. (A, B) Compound E
reduced ISF Aβx-40 and Aβx-42 levels by 42% and 44%, respectively, during the first 8
hours after each treatment compared to vehicle-treated controls. ISF Aβx-40 and Aβx-42
exhibited more modest decreases during hours 8-16 after Compound E treatment and
were no different from controls during hours 16-24 (n=4/group, two-way ANOVA with
post-hoc Bonferroni tests; *=p≤0.05). (C) Expressed as relative levels over 24 hours,
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mice treated with Compound E for 7 days exhibited a 22% decrease in ISF Aβx-40 and a
25% decrease in Aβx-42 compared to controls (n=4/group; Paired t-test; *= p≤0.05).
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Supplemental figure 1. Schematic representation of open- and thinned-skull
cranial window preparations. (A) In open-skull cranial window preparations, a
craniotomy is performed to remove a large (6 mm diameter) section of skull. A
glass coverslip is placed over the resultant window and acrylic is used to cement
the coverslip in place. (B) In thinned-skull cranial window preparations, a small
(< 0.8 mm diameter) section of skull is thinned using a high-speed drill and
microknife until transparent. (Insets) In each preparation, the pial vasculature is
clearly visible through the cranial window and serves as a guide to facilitate
locating the same plaque over multiple imaging sessions.
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Supplemental figure 2. Laser power does not affect plaque size determination. (A)
Several high power fields containing multiple plaques were repeatedly imaged using
increasing laser power (14-20%) while detection gain and amplification parameters were
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held constant. No significant differences in plaque size determination were present
across laser intensities. (B) Representative micrographs illustrate no difference in
average plaque size as a function of laser power. (C, D). A pre-set threshold (threshold =
mean + 4*(standard deviation); Sigmascan Pro Image Analysis software) was used to
capture methoxy-X04-labeled plaques while excluding background staining in all crosssectional area calculations.
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Supplemental figure 3. Ten month-old APP/PS1 mice do not exhibit significant
average plaque growth. (A) Average plaque growth was not significant at 7-day or (B)
90-day intervals in 10 month-old APP/PS1 mice. (C) Average absolute plaque size
sampled in 6 month-old mice appeared smaller than that in 10 month-old mice and
plaques imaged in 6 month-old mice showed greater mean growth than those imaged in
10 month-old mice. (D) Newly formed plaques are significantly smaller than pre-existing
plaques in 6 month-old animals imaged at a 28-day interval (n=4 mice/group; Student’s ttest, *= p≤0.05).
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Supplemental figure 4. Frequency distribution plots indicate that plaque growth
dynamics are related to animal age and skull window preparation. (A) Plaques
imaged under thinned-skull window preparations in 6 month-old APP/PS1 mice exhibited
modest growth over 7-day intervals and more robust growth over 28- and 90-day
intervals. (B) Plaque growth was less pronounced under thinned-skull preparations in 10
month-old mice. (C) Comparative analysis of plaque growth over a 28-day interval under
thinned- vs. open-skull window preparations in 6 month-old mice suggested that plaques
imaged under thinned-skull windows exhibited robust growth with little evidence of
regression. In contrast, plaques imaged under open-skull windows did not exhibit
significant growth but showed a greater frequency of regression.
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Vehicle Compound E

Supplemental figure 5. γ-secretase inhibition does not alter plaque growth in 10
month-old APP/PS1 mice. Ten month-old APP/PS1 mice were treated daily with
vehicle or Compound E (3 mg/kg, i.p.) for 7 days (n=4 mice/group). Plaque growth is
expressed as a percentage of cross-sectional area at the initial imaging session. No
significant difference in average plaque size was present between groups.
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Supplemental figure 6. Compound E transiently reduces ISF Aβ concentration.
Three month-old APP/PS1 mice were treated with a single dose of Compound E (3
mg/kg, i.p.) while cortical in vivo microdialysis was performed to continuously measure
ISF Aβ levels in living mice. (A, B) Compound E treatment decreased ISF Aβ1-x by 27%
during the first 8 hours after treatment and had no effect during the remaining 16 hours of
sample collection (n=6).
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Chapter 3.
Neuronal activity regulates the regional vulnerability to amyloid-β deposition
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PREFACE
The work in this chapter was published in the June 2011 issue of Nature Neuroscience.
The majority of the work was performed by Adam W. Bero with technical assistance
from Ping Yan (laboratory of Jin-Moo Lee), Jee Hoon Roh, Floy Stewart and John R.
Cirrito (laboratory of John R. Cirrito).
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ABSTRACT
Amyloid-β (Aβ) plaque deposition in specific brain regions is a pathological hallmark of
Alzheimer's disease. However, the mechanism underlying the regional vulnerability to
Aβ deposition in Alzheimer's disease is unknown. Herein, we provide evidence that
endogenous neuronal activity regulates the regional concentration of interstitial fluid
(ISF) Aβ, which drives local Aβ aggregation. Using in vivo microdialysis, we show that
ISF Aβ concentrations in several brain regions of APP transgenic mice before plaque
deposition were commensurate with the degree of subsequent plaque deposition and with
the concentration of lactate, a marker of neuronal activity. Furthermore, unilateral
vibrissal stimulation increased ISF Aβ, and unilateral vibrissal deprivation decreased ISF
Aβ and lactate, in contralateral barrel cortex. Long-term unilateral vibrissal deprivation
decreased amyloid plaque formation and growth. Our results suggest a mechanism to
account for the vulnerability of specific brain regions to Aβ deposition in Alzheimer's
disease.
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INTRODUCTION
Alzheimer's disease is the most common type of dementia and is characterized by
insidious degeneration of brain systems that subserve memory and cognition.
Accumulation and aggregation of the Aβ peptide in the extracellular space of the brain is
a pathological hallmark of Alzheimer's disease. Aβ is produced in neurons by sequential
proteolytic cleavage of the amyloid precursor protein (APP) by β- and γ-secretase
(Selkoe, 2001). Under normal conditions, Aβ is secreted into the interstitial fluid (ISF) of
the brain, where it is present in a soluble form throughout life (Cirrito et al., 2003). In
Alzheimer's disease pathogenesis, Aβ aggregates into higher-order species such as
soluble oligomers and insoluble amyloid plaques in a concentration-dependent manner.
As amyloid plaques are extracellular structures, the concentration of Aβ in the ISF is
likely to be a key determinant of whether and when Aβ will aggregate (Meyer-Luehmann
et al., 2003). Consistent with this hypothesis, we have recently shown that ISF Aβ
concentration is closely associated with amyloid plaque growth and formation in vivo
(Yan et al., 2009).
In Alzheimer's disease–affected brain, amyloid plaque deposition is most prominent in
the 'default-mode network'—a network of brain regions that shows elevated metabolic
activity and aerobic glycolysis during undirected mentation (Raichle et al., 2001;
Buckner et al., 2005; Buckner et al., 2008; Buckner et al., 2009; Vaishnavi et al., 2010;
Vlassenko et al., 2010). Indeed, default network dysfunction is present in Alzheimer's
disease patients (Greicius et al., 2004) as well as cognitively normal adults who harbor
appreciable amyloid burden (Hedden et al., 2009; Sperling et al., 2009). However, the
mechanism underlying the vulnerability of specific brain regions to amyloid deposition in
54

Alzheimer's disease is not known. Given the near direct proportionality between neuronal
energy consumption and neurotransmitter cycling in vivo (Hyder et al., 2006), this
correspondence raises the possibility of a relationship between patterns of neuronal
activity throughout life and the topography of amyloid deposition in Alzheimer's disease.
Evidence from our laboratory and others suggests that synaptic activity regulates Aβ
production and secretion into the ISF in vitro (Kamenetz et al., 2003; Wei et al., 2010)
and in vivo (Cirrito et al., 2005; Cirrito et al., 2008). For example, electrical stimulation
of the perforant pathway increases ISF Aβ in hippocampus, whereas blockade of synaptic
vesicle exocytosis decreases ISF Aβ. However, the relationship between endogenous
regional differences in neuronal activity and amyloid deposition remains unknown.
Herein, we provide data suggesting that regional differences in endogenous neuronal
activity dynamically regulate Aβ levels and have implications for the development of Aβrelated pathology.
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MATERIALS AND METHODS
Mice.
Male and female Tg2576+/− (Hsiao et al., 1996) × B6SJL mice (Taconic Farms) were
used at 17.5 ± 0.5 months of age for Aβ immunohistochemistry and X-34 staining
experiments and 3.5 ± 0.5 months of age for all other experiments. Male and female wildtype (B6SJL) mice were used at 5.5 ± 0.5 months of age. Male and female APPswe;
PSEN1ΔE9 (Jankowsky et al., 2004) × B6C3 (APP/PS1; The Jackson Laboratory) were
used at 7–7.5 months of age. When two or more groups of mice were compared, groups
were sex-matched. Mice were given ad libitum access to food and water. All
experimental protocols were approved by the Animal Studies Committee at Washington
University.
Plaque deposition analyses.
Brain tissue was dissected and flash-frozen for 1 min in isopentane chilled with dry ice
before sectioning on a cryostat (Leica). Serial coronal sections (30-μm section thickness)
were collected from the genu of the corpus callosum to caudal hippocampus. Sections
(each separated by 180 μm) were stained with biotinylated 3D6 antibody (anti-Aβ1–5;
generous gift from Eli Lilly) to visualize Aβ immunopositive plaques or X-34 dye to
visualize fibrillar amyloid plaques. Immunostained sections were scanned using a
NanoZoomer slide scanner (Hamamatsu Photonics). X-34–stained sections were imaged
using a fluorescence microscope (Nikon) and images were captured using a digital CCD
color camera (QCapture Pro version 6.0, QImaging). Quantitative analysis of percentage
area covered by immuno- or X-34–positive staining was performed as described
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previously (Kim et al., 2009b). Briefly, images of immunostained sections were exported
with NDP viewer software (Hamamatsu Photonics), converted to 8-bit grayscale using
ACDSee Pro 2 software (ACD Systems), thresholded to highlight Aβ-specific staining
and analyzed using ImageJ software (National Institutes of Health). Images of X-34–
stained sections were converted to 16-bit grayscale, thresholded to highlight X-34–
specific staining and analyzed using ImageJ software. A mouse brain atlas (Franklin and
Paxinos, 1996) was used to identify piriform cortex, cingulate cortex, barrel cortex,
hippocampus and striatum for quantitative analysis of immuno- and X-34–positive
staining.
In vivo microdialysis.
In vivo microdialysis used to measure Aβ in the brain ISF of awake, freely behaving mice
was performed essentially as described (Cirrito et al., 2003). Briefly, guide cannulae (BRstyle, Bioanalytical Systems) were stereotaxically implanted into piriform cortex (bregma
+ 1.0 mm, 3.8 mm lateral to midline, 1.2 mm below the dura at a 21° angle), barrel cortex
(at bregma, 2.0 mm lateral to midline, 1.0 mm below the dura at a 32° angle),
hippocampus (bregma − 3.1 mm, 2.5 mm lateral to midline, 1.2 mm below the dura at a
12° angle) or striatum (bregma + 0.5 mm, 1.8 mm lateral to midline, 1.4 mm below the
dura at a 0° angle) for measurement of steady-state Aβ and lactate. For vibrissal trimming
and stimulation experiments, guide cannulae were implanted into posterior barrel cortex
(bregma − 1.5 mm, 1.7 mm lateral to midline, 0.7 mm below the dura at a 49° angle).
Probe placement in the region of interest was verified by cresyl violet staining.
Microdialysis probes (2 mm; 38 kDa molecular weight cut-off; BR-style, BioAnalytical
Systems) were connected to a syringe pump (Stoelting) and artificial cerebrospinal fluid,
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pH 7.35, containing (in mM) 1.3 CaCl2, 1.2 MgSO4, 3 KCl, 0.4 KH2PO4, 25 NaHCO3
and 122 NaCl was continuously perfused through the microdialysis probe at a constant
flow rate. For measurement of Aβx–40, Aβ1–x and lactate in Tg2576 mice, a flow rate of
1.0 μl min−1 was used. For measurement of Aβx–42 in Tg2576 mice, a flow rate of 0.3 μl
min−1 was used. For measurement of Aβx–40 and lactate in wild-type (B6SJL) mice, a
flow rate of 0.5 μl min−1 was used. For PTX and TTX infusion by means of reverse
microdialysis into hippocampi of young Tg2576 mice, a stable baseline of ISF Aβx–40 and
lactate concentrations was obtained before drug treatment began. PTX (12.5 μM) was
continuously infused for 12 h. After a 5 h washout period, TTX (5 μM) was continuously
infused for 16 h before concluding the experiment. For ISF Aβ half-life experiments, a
stable baseline of ISF Aβx–40 was obtained before intraperitoneally injecting each mouse
with 10 mg kg−1 of the γ-secretase inhibitor compound E (custom synthesis, AsisChem).
The plot of the common logarithm of percent baseline ISF Aβx–40 concentration versus
time after injection was linear in each region, suggesting first-order kinetics. Therefore,
the elimination half-life of ISF Aβx–40 in each mouse was calculated using the slope of the
linear regression from log(percent baseline ISF Aβx–40) versus time as described
previously2. In vibrissal trimming experiments, stable baseline concentrations of ISF Aβx–
40

and ISF lactate were obtained before all mystacial vibrissae contralateral to the

microdialysis probe were trimmed to within 1 mm of the facial pad using fine surgical
scissors (Roboz). Vibrissae ipsilateral to the microdialysis probe remained intact
throughout the experiment. In vibrissal stimulation experiments, mice were anesthetized
with ketamine-xylazine (130.4 and 20.1 mg kg−1, respectively) during the microdialysis
sampling period. All vibrissae ipsilateral to the microdialysis probe were trimmed to

58

within 1 mm of the facial pad using fine surgical scissors (Roboz). Mechanical vibrissal
stimulation was performed by gently brushing vibrissae contralateral to the microdialysis
probe using a cotton-tipped applicator for 30 min (5–7 Hz, 4 s burst, 4 s inter-burst
interval). In sleep/wake experiments, guide cannulae were implanted into hippocampus 2
weeks before microdialysis began. Mice were habituated to the microdialysis sampling
environment for 3 d and microdialysis samples collected during this period were
discarded. On the fourth day, samples were collected and stored for analysis.
ELISA.
Microdialysis samples were analyzed for Aβx–40, Aβx–42 or Aβ1–x using a species-specific
sandwich enzyme-linked immunosorbent assay (ELISA). Briefly, Aβx–40, Aβx–42 and Aβ1–
x

were captured using monoclonal antibodies targeting amino acids 35–40 (HJ2,

generated in-house), 37–42 (HJ7.4, generated in-house) and 13–28 (m266) of Aβ,
respectively. For Aβx–40 and Aβx–42 assays, a biotinylated central-domain monoclonal
antibody (HJ5.1, generated in-house) followed by streptavidin–poly-horseradish
peroxidase-40 (Fitzgerald) was used for detection. For Aβ1–x assays, a biotinylated Nterminal-domain monoclonal antibody (3D6B) followed by streptavidin–poly-horseradish
peroxidase-20 was used for detection (Fitzgerald). The antibodies m266 and 3D6B were
generous gifts from Eli Lilly. All assays were developed using Super Slow ELISA TMB
(Sigma) and read on a Bio-Tek Synergy 2 plate reader at 650 nm.
Intraparenchymal EEG recording.
Depth EEG recording was performed as previously described (Cirrito et al., 2005).
Briefly, bipolar recording electrodes (A-M Systems) were affixed to the microdialysis
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guide cannula and stereotaxically implanted into the hippocampus. Electrodes extended
approximately 1 mm from the tip of the guide cannula to position the electrodes near the
center of the 2-mm microdialysis membrane. EEG activity was assessed using a P511K
A.C. preamplifier (Grass Technologies), digitized with a DigiData 1440A data
acquisition system (Molecular Devices) and recorded digitally using pClamp 10.2
(Molecular Devices).
Lactate assay.
An enzymatic lactate assay kit (BioVision) was used to measure lactate present in ISF
samples according to the manufacturer's instructions. Assays were read on a Bio-Tek
Synergy 2 plate reader at 570 nm.
Western blot.
Dissected tissue from piriform, barrel and cingulate cortices was homogenized in
radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 50 mM Tris, 0.5%
(wt/vol) deoxycholic acid, 1% (vol/vol) Triton X-100, 0.1% (wt/vol) SDS, 2.5 mM
EDTA and a protease inhibitor cocktail (Calbiochem), pH 8.0; 10 μl mg−1 tissue wet
weight) with a manual wand. Dissected tissue from hippocampus and striatum was
homogenized in RIPA buffer by sonication. Tissue homogenates were centrifuged at
13,500g at 4 °C for 15 min and supernatant was saved for analysis. In addition to
normalizing western blot results to equal amounts of brain wet weight loaded per lane, a
loading control was also performed for each tissue sample. Equal volumes of tissue
samples were spiked with 5 μg fluorescein-conjugated BSA (Biosearch Technologies) to
serve as a loading control and equal volumes of tissue homogenate were separated by 4–
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12% Bis-Tris gel electrophoresis (Invitrogen) under reducing conditions. Nitrocellulose
blots (0.2 μm pore size, Bio-Rad) were probed for full-length APP using 6E10 antibody
(human-specific; Covance) or APP CTFs using CT695 antibody (reactivity with human
and mouse; Invitrogen). Normalized band intensity was quantified using ImageJ
(National Institutes of Health).
Sleep/wake monitoring.
Polysomnographic sleep-wake cycle analysis of mice was performed as described
previously (Kang et al., 2009). Briefly, EEG and electromyogram (EMG) electrodes were
implanted simultaneously with the microdialysis guide cannula. For EEG recording, two
stainless steel screws attached to wire electrodes were placed over the right frontal bone
(bregma + 1.0 mm, 1.5 mm lateral to midline) and the right parietal bone (bregma − 3.0
mm, 2.5 mm lateral to midline). Two wire electrodes were directly inserted into the neck
musculature for EMG recording. The ground electrode was placed on the skull over the
cerebellum. Insulated leads from the EEG and EMG electrodes were soldered to a miniconnector. After surgery, mice were housed in 12 h light/12 h dark conditions (light
phase beginning at 6 a.m.) for 2 weeks before recording began. To monitor the sleepwake cycle, mice were transferred to recording cages maintained in 12 h light/12 h dark
conditions (light phase beginning at 6 a.m.) and the mini-connector was connected to
flexible recording cables. Mice were habituated to the recording cages for 3 d. At the
conclusion of the habituation period, EEG and EMG recording began simultaneously
with microdialysis sample collection. EEG and EMG signals were displayed on a monitor
and stored in a computer for off-line analysis of sleep states. EEG and EMG recordings
were assessed using a P511K A.C. preamplifier (Grass Technologies), digitized with a
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DigiData 1440A data acquisition system (Molecular Devices) and recorded digitally
using pClamp 10.2 (Molecular Devices). EEG and EMG signals were filtered (EEG: high
pass, 1 Hz; low pass, 30 Hz; EMG: high pass, 10 Hz; low pass, 100 Hz) and used to
identify vigilance states. EEG and EMG recordings were scored semiautomatically using
sleep scoring software (SleepSign, Kissei Comtec) and binned into 10-s epochs as
wakefulness, rapid eye movement (REM) sleep and non-REM sleep per standard criteria
of rodent sleep. Semiautomatic sleep scoring was visually inspected and corrected when
appropriate.
Thinned-skull cranial window surgery.
Thinned-skull cranial windows were prepared on the day of the first multiphoton imaging
session as described previously (Yan et al., 2009). Briefly, mice were anesthetized under
volatile isoflurane and the skin and periosteum were removed to expose the skull. A highspeed drill and microsurgical blade (Surgistar) were used to thin the skull until it was
transparent and flexible. One cranial window (2 × 2 mm) was prepared over barrel cortex
(bregma − 1.5 mm, 3.5 mm lateral to midline) of each hemisphere.
In vivo multiphoton microscopy.
Longitudinal multiphoton microscopy to monitor amyloid plaque growth was performed
as described previously (Yan et al., 2009). Briefly, mice were injected intraperitoneally
with the fluorescent amyloid-binding compound methoxy-X04 [(Klunk et al., 2002); 5
mg ml−1] 24 h before each multiphoton imaging session. Mice were mounted on a
custom-built stereotaxic apparatus and a small ring of molten bone wax was applied to
the skull surrounding the perimeter of the window to create a water immersion chamber.
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The cranial window was centered under the objective lens on a two-photon microscope
(LSM 510 META NLO system (Carl Zeiss) with a Cameleon Ti:sapphire laser (Coherent
Inc.)). Two-photon fluorescence was generated with 750 nm excitation and fluorescence
emission was detected at 435–485 nm. A 10X water-immersion objective (numerical
aperture 0.33, Zeiss) was used to create a site map during initial imaging and a 40X
water-immersion objective (numerical aperture 0.75, Zeiss) was used for high-resolution
quantification of individual amyloid plaques. Incremental z-stack image series (step
distances 10 and 5 μm under 10X and 40X objectives, respectively) were acquired from
the skull surface to approximately 200 μm into cortex. To determine the effect of longterm vibrissal deprivation on amyloid plaque formation and growth, the same sites of
each hemisphere of barrel cortex in each mouse were imaged on day 0 and day 28.
Collapsed z-stack images of each amyloid plaque were measured by cross-sectional area
using SigmaScan Pro Image Analysis Software (Systat Software) as previously described
(Yan et al., 2009). Plaques were excluded from analysis if they were located at the edge
of the window or showed fluorescence intensity less than the mean intensity of an
adjacent background region or if the image acquisition was affected by motion artifacts
from heartbeat or respiration.
Double immunofluorescence.
To compare astrocytic and microglia activation in barrel cortex after long-term vibrissal
deprivation, mice were transcardially perfused with 0.9% saline followed by 4%
paraformaldehyde in 0.1 M phosphate buffer immediately after the final multiphoton
imaging session. Brains were removed and postfixed in 4% paraformaldehyde for another
4 h. Coronal free-floating sections (50 μm thick) were cut on a cryostat (Leica). Sections
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were incubated overnight at 4 °C in a combination of mouse anti–glial fibrillary acidic
protein monoclonal antibody (Sigma) and rabbit anti-Iba1 (Wako Chemicals). A
secondary antibody mixture of Alexa Fluor 488–conjugated donkey anti–mouse IgG
(Invitrogen) and Cy3-conjugated donkey anti–rabbit IgG (Jackson ImmunoResearch
Laboratories) was used for detection. Sections were imaged using a confocal microscope
(Zeiss LSM).
Statistical analysis.
Statistical significance was determined by two-tailed t-test if two groups were compared.
When variance differed significantly between groups, Welch's t-test was used. One-way
ANOVA followed by Tukey's post hoc test for multiple comparisons tests were used
when more than two groups were compared. Correlation was determined using Pearson
product moment correlation test. All statistical analyses were performed using Prism
version 4.0 for Windows (GraphPad). Values were accepted as significant if P < 0.05.
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RESULTS
Regional plaque deposition in aged Tg2576 mouse brain
In Alzheimer's disease, amyloid deposition is most prominent in brain areas that comprise
the default network. Core regions of the default network in human cortex include medial
and lateral parietal, posterior cingulate, retrosplenial and medial prefrontal areas, as well
as the hippocampal formation. To begin to elucidate the mechanisms that regulate regionspecific amyloid deposition, we first characterized the distribution of Aβ deposition in
APP transgenic (Tg2576) mice, which express a mutated form of amyloid precursor
protein (APP). Brain sections from Tg2576 mice 17.5 ± 0.5 months old were
immunostained with biotinylated 3D6 antibody, to Aβ amino acids 1-5 (anti-Aβ1–5) to
determine the percentage area occupied by Aβ plaques in brain regions of interest. We
found progressively higher Aβ plaque burden across barrel (3.96% ± 0.69), cingulate
(9.00 ± 1.59) and piriform (16.54 ± 4.07) cortices (Fig. 1a–c). Aβ plaque burden in
hippocampus (5.51 ± 1.45) was similar to that in barrel cortex; striatum (0.62 ± 0.11) had
the least plaque deposition of all regions examined (Fig. 1a–c). Tg2576 mice thus show
region-specific Aβ deposition that is similar to the pattern observed in human
Alzheimer's disease.
To determine whether fibrillar amyloid plaques showed a distribution similar to Aβ
immunopositive plaques, we stained brain sections from aged Tg2576 mice with the
amyloid-specific dye X-34. In accord with the pattern of Aβ immunopositive plaque
deposition, we found that the percentage area occupied by X-34–positive amyloid plaque
deposition was progressively higher in barrel (0.27% ± 0.03), cingulate (1.22 ± 0.34) and
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piriform (2.90 ± 0.40) cortices. Amyloid deposition in hippocampus (0.43 ± 0.09) was
similar to that in barrel cortex. Amyloid was not detected in striatum (Fig. 1d–i). These
results suggest that regional differences in Aβ and amyloid plaque deposition are present
in aged Tg2576 mouse brain and that Tg2576 mice represent a useful model in which to
examine mechanisms underlying regional vulnerability to Aβ and amyloid plaque
deposition.
ISF Aβ predicts region-specific plaque deposition
As we have previously demonstrated that the concentration of Aβ in the ISF is closely
associated with amyloid plaque growth and formation in vivo, we hypothesized that the
steady-state concentration of ISF Aβ in each brain region early in life, before plaque
deposition, would predict the degree of subsequent plaque deposition in aged mice. To
test this hypothesis, we performed in vivo microdialysis to measure steady-state ISF Aβ
in brain regions of young (age 3.5 ± 0.5 months) Tg2576 mice before the onset of plaque
deposition. Using an Aβx–40-specific ELISA, we found that steady-state ISF Aβx–40
concentrations were greatest in piriform cortex (2,296.55 ± 308.35 pg ml−1), intermediate
in barrel cortex (824.16 ± 112.81) and hippocampus (1,150.10 ± 130.71) and lowest in
striatum (184.74 ± 25.71; Fig. 2a). ISF Aβx–40 concentrations in young mice before
plaque deposition therefore predict the amount of both Aβ (Fig. 2b) and fibrillar amyloid
(Fig. 2c) plaque deposition in aged mice in a region-specific manner. We next sought to
determine whether the concentration of the more amyloidogenic form of Aβ, Aβx–42, in
each brain region of young mice predicts the level of plaque deposition in aged mice.
Consistent with our data regarding regional ISF Aβx–40 concentrations, an Aβx–42-specific
ELISA showed that ISF Aβx–42 concentration was greatest in piriform cortex (104.94 ±
66

30.21 pg ml−1), intermediate in barrel cortex (48.24 ± 6.79) and hippocampus (44.31 ±
8.25) and lowest in striatum (9.47 ± 1.46; Fig. 2d). Therefore, regional ISF Aβx–42
concentration in young mice also predicts the degree of regional Aβ (Fig. 2e) and
amyloid (Fig. 2f) plaque deposition in aged mice.
Next, we assessed whether regional differences in ISF Aβ levels were present in young
wild-type (B6SJL) mice. In accord with our findings in APP transgenic mice, mouse ISF
Aβx–40 concentrations were significantly greater in hippocampus (148.51 ± 17.93 pg ml−1)
than in striatum (47.4 ± 11.46; P = 0.0032; Supplementary Fig. 1a). This result suggests
that regional differences in ISF Aβ concentration are intrinsic to normal brain physiology.
Together, these data suggest that steady-state ISF Aβ levels in young mice predict the
degree of Aβ and amyloid plaque deposition in a region-specific manner.
ISF lactate predicts region-specific ISF Aβ
As the default network shows elevated cerebral metabolism during resting conditions,
one possibility is that elevated metabolic activity in specific brain regions throughout life
regulates the ultimate distribution of amyloid deposition. Previous data suggest that
synaptic activity regulates soluble extracellular Aβ levels in vitro and in vivo. As ISF Aβ
concentration is closely associated with amyloid plaque growth and formation, we
hypothesized that regional differences in baseline neuronal activity would be proportional
to regional steady-state ISF Aβ concentration in Tg2576 mice before the onset of plaque
deposition. Previous data suggest that neuronal activity directly regulates extracellular
lactate concentration in vitro (Pellerin and Magistretti, 1994) and in vivo (Uehara et al.,
2008). To further establish ISF lactate as a marker of neuronal activity, we
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pharmacologically manipulated neuronal activity during in vivo microdialysis with
concurrent intraparenchymal electroencephalogram (EEG) recording in young Tg2576
mice. To determine whether increased neuronal activity increases ISF lactate and Aβ, we
administered picrotoxin (12.5 μM; PTX), a GABAA receptor antagonist, by means of
reverse microdialysis. Infusion of PTX into hippocampus increased hippocampal EEG
amplitude (Fig. 3a) and ISF lactate compared to basal conditions (PTX, 129.6 ± 6.4% of
basal; basal, 100.0 ± 8.76; P = 0.0342; Fig. 3b and Supplementary Fig. 2a). In accord
with previous data (Cirrito et al., 2008), PTX also significantly increased hippocampal
ISF Aβx–40 concentration relative to basal conditions (PTX, 125.8 ± 5.16% of basal; basal,
100.0 ± 5.21; P = 0.0126; Fig. 3c and Supplementary Fig. 2b). To determine whether
depression of local neuronal activity reduces ISF lactate and Aβ, we administered the
voltage-gated sodium channel blocker tetrodotoxin (5 μM; TTX) by means of reverse
microdialysis. Compared to basal conditions, TTX reduced EEG amplitude (Fig. 3a) and
ISF lactate in hippocampus (TTX, 69.62 ± 2.69% of basal; basal, 100.0 ± 8.75; P =
0.0160; Fig. 3b and Supplementary Fig. 2a). Consistent with previous data (Cirrito et al.,
2005), TTX infusion also reduced ISF Aβx–40 concentration (TTX, 67.11 ± 2.94% of
basal; basal, 100.0 ± 5.21; P = 0.0015; Fig. 3c and Supplementary Fig. 2b). Across basal,
PTX treatment and TTX treatment conditions, ISF lactate significantly correlated with
ISF Aβ (Pearson r = 0.7645, P < 0.0001; Fig. 3d). Together, these data suggest that
increasing neuronal activity increases, and decreasing neuronal activity decreases, ISF
lactate concentration and suggest that ISF lactate is a marker of neuronal activity in vivo.
To test the hypothesis that regional differences in ISF lactate are proportional to regional
steady-state ISF Aβ concentration before the onset of plaque deposition, we next
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performed in vivo microdialysis to measure steady-state ISF lactate in several brain
regions of young Tg2576 mice. We found that ISF lactate was greatest in piriform cortex
(142.47 ± 10.19% of striatal value), intermediate in barrel cortex (124.94 ± 11.58) and
hippocampus (119.3 ± 10.53) and lowest in striatum (100.0 ± 11.93). ISF lactate was thus
commensurate with steady-state ISF Aβx–40 (Fig. 4a) and Aβx–42 (Fig. 4b) concentrations
in young Tg2576 mice. Moreover, steady-state ISF lactate was proportional to
subsequent Aβ (Fig. 4c) and amyloid (Fig. 4d) plaque deposition on a region-specific
basis. To test whether the relationship between basal ISF lactate and ISF Aβ also held in
wild-type mice, we measured ISF lactate in hippocampus and striatum of young B6SJL
mice. In accord with our data in Tg2576 mice, ISF lactate concentration was closely
associated with mouse ISF Aβx–40 concentration in young B6SJL mice (Supplementary
Fig. 1b). These results suggest that regional differences in ISF lactate in young mice
before plaque deposition are closely associated with steady-state ISF Aβ concentration
and subsequent plaque deposition in Tg2576 mice.
As steady-state ISF Aβ concentration is the result of a balance between the rates of Aβ
production and clearance, we next sought to determine whether regional differences in
ISF Aβ clearance rate might be associated with steady-state ISF Aβ levels in young
Tg2576 mice and might therefore contribute to region-specific Aβ deposition. To assess
this possibility, we performed in vivo microdialysis in several brain regions of young
Tg2576 mice. During the microdialysis sampling period, mice were treated
intraperitoneally with compound E (10 mg per kilogram body weight), a potent γsecretase inhibitor, to rapidly halt Aβ synthesis and permit determination of ISF Aβ
elimination half-life (t1/2) as previously described (Cirrito et al., 2003). ISF Aβx–40 t1/2 did
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not differ significantly across barrel cortex (0.99 ± 0.11 h), hippocampus (0.97 ± 0.03)
and striatum (1.21 ± 0.08; P = 0.1175) in the brains of young Tg2576 mice
(Supplementary Fig. 3a,b), suggesting that regional variation in ISF Aβ clearance rate is
not sufficient to account for the pattern of plaque deposition in aged Tg2576 mice.
APP processing does not predict regional ISF Aβ levels
Amyloidogenic processing of full-length APP by β- and γ-secretase is necessary for Aβ
generation. β-secretase cleavage of APP holoprotein produces C-terminal fragment
(CTF)-β, whereas non-amyloidogenic processing of APP by α-secretase produces CTF-α
and precludes Aβ generation. Differential expression or processing of APP holoprotein
across brain regions could thus contribute to regional differences in steady-state ISF Aβ
concentrations and plaque deposition. To test this possibility, we performed western blot
analyses to measure APP holoprotein, CTF-β and CTF-α across cortical regions that
harbor differential ISF Aβ concentrations and develop differential plaque burden. Despite
marked differences in steady-state ISF Aβ concentrations and plaque deposition,
expression levels of full-length APP, CTF-β and CTF-α were similar in piriform,
cingulate and barrel cortices (P = 0.9437, 0.9821 and 0.6348 for APP, CTF-β and CTF-α,
respectively; Supplementary Fig. 4a–c).
To determine the role of APP expression and processing in region-specific regulation of
Aβ concentration in subcortical structures, we next measured APP holoprotein, CTF-β
and CTF-α in whole cortex, hippocampus and striatum. Relative to hippocampus and
striatum, APP holoprotein expression was significantly greater in cortex (P = 0.0017;
Supplementary Fig. 4d,f). CTF-β expression was significantly lower in striatum than in
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hippocampus (P = 0.0245; Supplementary Fig. 4e,f), whereas CTF-α expression did not
differ across cortex, hippocampus and striatum (P = 0.9761; Supplementary Fig. 4e,f).
Together, these results suggest that regional APP expression and processing profiles are
not associated with local differences in steady-state ISF Aβ or plaque deposition and are
thus not sufficient to account for the pattern of amyloid deposition observed in Tg2576
mice.
Vibrissal activity regulates ISF Aβ levels
The present data suggest that regional differences in basal ISF lactate concentrations are
closely associated with steady-state ISF Aβ concentrations and predict subsequent plaque
deposition. We next sought to determine whether a causal relationship between
physiological neuronal activity and both steady-state ISF Aβ and lactate concentrations
exists in vivo. In rodents, each vibrissa is somatotopically mapped onto a defined cluster
of neurons termed a 'barrel' in primary somatosensory cortex (Woolsey and Van der
Loos, 1970). There, neurons in each barrel respond to stimulation of the vibrissa to which
they are synaptically connected. Vibrissal stimulation increases (Melzer et al., 1985),
whereas vibrissal removal decreases (Durham and Woolsey, 1978), neuronal activity in
barrel cortex. Therefore, the vibrissae-barrel system represents a noninvasive
physiological circuit in which to examine the relationship between physiological neuronal
activity and ISF Aβ concentrations in vivo.
To determine whether a manipulation that causes a physiological reduction in neuronal
activity could reduce ISF Aβ concentrations, we performed vibrissal deprivation during
in vivo microdialysis in barrel cortex of young Tg2576 mice. After establishing stable
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basal ISF Aβ concentrations, we trimmed all vibrissae contralateral to the microdialysis
probe to within 1 mm of the facial pad. Acute trimming of vibrissae reduced ISF Aβ in
barrel cortex by 22% compared to baseline (P = 0.0107; Fig. 5a,c). Similarly, trimming
of vibrissae reduced ISF lactate in barrel cortex by 19% relative to basal conditions (P =
0.0127; Fig. 5b,c).
To determine whether a manipulation that causes a physiological increase in neuronal
activity is sufficient to increase ISF Aβ concentrations, we next performed unilateral
mechanical vibrissal stimulation during in vivo microdialysis in barrel cortex of a
separate cohort of young Tg2576 mice anesthetized with ketamine-xylazine. Ketaminexylazine was chosen as the anesthetic agent because both basal and vibrissal stimulation–
induced neurophysiological responses under ketamine-xylazine anesthesia resemble the
responses elicited during wake and quiet sleep more closely than under other forms of
anesthesia (Rojas et al., 2006). We found that unilateral mechanical vibrissal stimulation
(5–7 Hz, 4 s burst, 4 s inter-burst interval) for 30 min increased ISF Aβx–40 in barrel
cortex by 31% relative to control conditions (P = 0.0446; Fig. 5d).
ISF lactate levels show diurnal fluctuation
The sleep/wake cycle is associated with diurnal fluctuation of ISF Aβ; ISF Aβ
concentration is greater during wakefulness and lesser during sleep (Kang et al., 2009).
Previous data from humans and animal models suggest that periods of wakefulness are
associated with increased synaptic strength and periods of sleep are associated with
decreased synaptic strength (Riedner et al., 2007; Vyazovskiy et al., 2008b; Gilestro et
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al., 2009). Therefore, we reasoned that diurnal fluctuation of ISF Aβ might be linked with
lactate levels throughout the sleep/wake cycle.
To assess this possibility, we performed in vivo microdialysis in hippocampi of young
Tg2576 mice housed in 12 h light/12 h dark conditions. Consistent with our previous
findings, ISF Aβ1–x concentrations were 21% greater during the dark period than during
the light period (P = 0.0314; Fig. 6a,c). Moreover, ISF lactate concentrations were 23%
greater during the dark period than during the light period (P = 0.0066; Fig. 6b,c). ISF
Aβ1–x concentrations were thus correlated with ISF lactate concentrations across the
sleep/wake cycle (Pearson r = 0.6351, P < 0.0001; Fig. 6d). As mice spent significantly
more time awake during the dark period than during the light period (dark, 51.32 ± 1.26
min awake per hour; light, 25.02 ± 2.15; P < 0.0001), these findings suggest that
wakefulness, ISF lactate and ISF Aβ are co-regulated and are consistent with the
hypothesis that diurnal fluctuation in neuronal activity contributes to the diurnal
fluctuation in ISF Aβ in vivo.
Vibrissal deprivation reduces plaque formation and growth
We have previously demonstrated that the concentration of ISF Aβ is closely related to
amyloid plaque growth and formation in vivo (Yan et al., 2009). As our present data
suggest that acute manipulations that alter neuronal activity modulate ISF Aβ
concentration, we hypothesized that manipulations that cause longer-term changes in
neuronal activity might modulate amyloid plaque growth and formation in vivo. To test
this hypothesis, we used 7-month-old APPswe; PSEN1ΔE9 [APP/PS1; (Jankowsky et al.,
2004)] bitransgenic mice because this strain develops aggressive fibrillar amyloid
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deposition beginning at 4–5 months of age. Using in vivo multiphoton microscopy,
amyloid plaques in barrel cortex of each hemisphere were visualized with methoxy-X04
under thinned-skull cranial windows to obtain basal measures of individual amyloid
plaque size. All vibrissae on the right side of the facial pad were subsequently trimmed to
within 1 mm of the face every other day for 28 d. At the conclusion of the 28-d vibrissal
deprivation period, amyloid plaques in barrel cortex of each hemisphere were reimaged
to assess the effect of vibrissal deprivation on individual amyloid plaque growth. We
found that plaque growth was decreased by 78% in the vibrissae-deprived relative to the
control hemisphere (P = 0.0014; Fig. 7a–e). Moreover, new amyloid plaque formation
was decreased by 65% in the deprived relative to the control hemisphere (P = 0.0367;
Fig. 7a–d,f).
To determine whether suppression of amyloid plaque growth and formation upon longterm vibrissal deprivation might be attributable to increased glial activation in barrel
cortex, brains were sectioned and stained for glial fibrillary acidic protein and Iba-1 to
visualize astrocytic and microglial activation, respectively. Confocal microscopy revealed
no qualitative difference in astrocytic (Supplementary Fig. 5a–c) or microglial
(Supplementary Fig. 5d–f) activation in the deprived hemisphere compared to the control
hemisphere. This result suggests that altered glial activation is not likely to contribute to
the observed suppression of amyloid plaque growth and formation upon long-term
vibrissal deprivation. Taken together, although long-term vibrissal deprivation results in
several changes in the brain, the present data are consistent with the hypothesis that
physiological neuronal activity regulates amyloid plaque growth dynamics in vivo.
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DISCUSSION
Aggregation of Aβ into higher-order structures such as extracellular amyloid plaques is a
necessary event in Alzheimer's disease pathogenesis. A fundamental feature of
Alzheimer's disease is the preferential deposition of amyloid plaques in distinct brain
regions. However, the mechanism by which specific brain regions are rendered
vulnerable to amyloid deposition in Alzheimer's disease has heretofore remained
unknown. As Aβ aggregation is closely related to ISF Aβ concentration in vivo,
elucidating the mechanisms that regulate ISF Aβ concentration has important
implications for understanding the etiology of region-specific Aβ deposition in
Alzheimer's disease. In the present work, we used in vivo microdialysis to show that ISF
Aβ concentrations measured in several brain regions of young Tg2576 mice months
before plaque deposition are directly proportional to the degree of subsequent plaque
deposition. Moreover, ISF Aβ concentrations in young mice are closely associated with
concentrations of baseline ISF lactate, a marker of neuronal activity, on a region-specific
basis. Furthermore, we show that physiological changes in neuronal activity are sufficient
to dynamically modulate ISF Aβ concentrations and amyloid plaque growth in vivo.
Collectively, our results suggest that regional differences in basal neuronal activity level
govern region-specific amyloid deposition through long-term regulation of steady-state
ISF Aβ concentration.
As sequential proteolysis of APP by β- and γ-secretase is necessary for Aβ generation,
several previous reports have examined the regional distribution of this triad as potential
mediators of region-specific Aβ deposition. However, the cerebral distribution of APP,
BACE1 and PSEN1 transcripts is not associated with the topography of Aβ deposition in
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human Alzheimer's disease (Bahmanyar et al., 1987; Goedert, 1987; Page et al., 1996;
Vassar et al., 1999) or APP transgenic mice (Irizarry et al., 1997; Bigl et al., 2000;
Irizarry et al., 2001). Moreover, the regional distribution of γ-secretase activity in APP
transgenic mouse brain does not correlate with the pattern of Aβ deposition (Goldstein et
al., 2007). Consistent with these previous reports, the present results suggest that
although differences in APP expression and processing are present across a subset of
brain areas in Tg2576 mice, the pattern of APP expression and processing is not
sufficient to account for the pattern of Aβ deposition. Together, these studies suggest that
more factors are necessary to drive region-specific Aβ deposition. In addition to regionspecific differences in neuronal activity potentially contributing to region-specific
differences in Aβ deposition, other possible contributors to the presence of Aβ in specific
neural networks include the spread of Aβ aggregates within and into the brain. For
instance, exogenous intracerebral (Meyer-Luehmann et al., 2003; Meyer-Luehmann et
al., 2006) or peripheral (Eisele et al., 2010) application of Aβ aggregates can seed
cerebral β-amyloidosis. Further, reports suggest that selective overexpression of APP in
the cell bodies of neurons in the entorhinal cortex of transgenic mice can elevate soluble
Aβ and produce amyloid plaque deposition in the synaptic terminal zone of the dentate
gyrus (Lazarov et al., 2002; Harris et al., 2010). Thus, transsynaptic propagation
mechanisms as well as spread of Aβ pathology through interconnected neural networks
might also contribute to the pattern of amyloid deposition observed in Alzheimer's
disease.
In the healthy human brain, a specific subset of brain regions—the default network—is
preferentially engaged during resting the state. Notably, amyloid deposition in
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Alzheimer's disease brain is most prominent in regions that comprise the default network.
These findings raise the possibility that patterns of normal cerebral metabolism may
influence the distribution of amyloid deposition in Alzheimer's disease. In accord with
this hypothesis, recent data suggest that the spatial distribution of resting-state aerobic
glycolysis (that is, glucose utilization in excess of that used for oxidative phosphorylation
despite sufficient oxygen to oxidize glucose to carbon dioxide and water) in cognitively
normal adults overlaps closely with the topography of amyloid deposition in Alzheimer's
disease. Our present data demonstrating that pharmacological manipulation of neuronal
activity directly regulates ISF lactate abundance are consistent with previous animal and
human studies and suggest that neuronal activity stimulates aerobic glycolysis in vivo.
Given that neuronal activity also increases Aβ production and secretion into the ISF,
regional differences in neuronal activity may underlie the spatial relationship between
resting-state aerobic glycolysis and amyloid deposition in Alzheimer's disease.
We have previously demonstrated that ISF Aβ concentrations fluctuate diurnally: ISF Aβ
concentration is significantly greater during waking conditions than during sleep (Kang et
al., 2009). Given that neuronal activity directly regulates ISF Aβ levels, we reasoned that
diurnal fluctuation of neuronal activity may contribute to diurnal fluctuation of ISF Aβ.
Indeed, previous data suggest that periods of wakefulness are associated with net synaptic
potentiation and periods of sleep are associated with synaptic downscaling and
depression (Vyazovskiy et al., 2008b). Here we show that ISF lactate concentration
fluctuates diurnally in a manner closely associated with the diurnal fluctuation of ISF Aβ.
These results are consistent with the notion that fluctuation of neuronal activity during
the sleep/wake cycle contributes to the diurnal fluctuation of ISF Aβ in vivo. This
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observation further supports the hypothesis that physiological neuronal activity
dynamically regulates ISF Aβ levels in vivo.
More generally, our results suggest that factors that elevate endogenous neuronal activity
over prolonged periods may accelerate progression of Aβ deposition. In support of this
hypothesis, recent functional magnetic resonance imaging data suggest that cognitively
normal apolipoprotein E (APOE) allele ε4 carriers show elevated resting-state activity in
the default network and increased hippocampal activation during a memory encoding
task compared to noncarriers (Filippini et al., 2009). Thus, in addition to apoE isoform–
dependent differences in apoE-Aβ interactions (Kim et al., 2009a), elevated lifetime
neuronal activity may be a complementary mechanism by which ε4 expression increases
Alzheimer's disease risk. Conversely, factors that reduce activity in vulnerable neural
networks may slow the progression of β-amyloidosis and reduce Alzheimer's disease risk.
For example, epidemiological evidence suggests that educational attainment is negatively
correlated with Alzheimer's disease risk (Flicker, 2010). As default network activity is
suppressed during cognitively demanding tasks, one possibility is that education reduces
Alzheimer's disease risk by reducing neuronal activity and Aβ generation within the
default network.
It is noteworthy that the regional distribution of lesions in mouse models of glutamateinduced excitotoxicity is similar to the distribution of Aβ deposition described herein
(Olney et al., 1997). As neuronal activity regulates both Aβ and glutamate release at the
synapse, the regional differences in basal neuronal activity described here may also
underlie the distribution of glutamate-induced excitotoxic lesions. A more detailed
understanding of the regional distribution of pre- and postsynaptic elements may provide
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insight regarding the structural basis of neuronal activity patterns in normal brain and
how patterns of neuronal and synaptic activity might contribute to a variety of
neurological lesions.
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Figure 1. Distribution of Aβ and amyloid plaque deposition in Tg2576 mouse brain.
(a,b) Representative brain sections from aged (17.5 ± 0.5 months old) Tg2576 mice
stained with biotinylated 3D6 antibody (anti-Aβ1–5) to visualize Aβ immunopositive
plaques (n = 7 per group). Scale bar, 750 μm. (c) Percentage brain area occupied by Aβ
deposition in barrel (BC), cingulate (CC) and piriform (PC) cortices and hippocampus
(HC) and striatum (ST). (d–h) Representative images of barrel cortex (d), cingulate
cortex (e), piriform cortex (f), hippocampus (g) and striatum (h) of aged Tg2576 mice
stained with the amyloid-binding dye X-34 (n = 6 per group). Scale bar, 50 μm. (i)
Percentage area occupied by X-34–positive amyloid deposition in brain regions
examined. *P < 0.05; **P < 0.01; ***P < 0.001 (one-way analysis of variance
(ANOVA), Tukey's post hoc test for multiple comparisons). Values represent mean ±
s.e.m.
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Figure 2. Steady-state ISF Aβ concentrations in young Tg2576 mice before plaque
deposition are associated with the level of region-specific plaque deposition in aged
Tg2576 mice. (a) In vivo microdialysis measurements of the steady-state concentrations
of ISF Aβx–40 in barrel cortex (BC), piriform cortex (PC), hippocampus (HC) and striatum
(ST) of 3.5 ± 0.5-month-old Tg2576 mice before the onset of plaque deposition (n = 5–6
per group; one-way ANOVA, Tukey's post hoc test for multiple comparisons). (b,c)
Steady-state concentrations of ISF Aβx–40 measured in each brain region of young
Tg2576 mice, plotted against subsequent Aβ (b) and amyloid (c) plaque deposition in
each brain region of aged Tg2576 mice. (d) In vivo microdialysis measurements of the
steady-state concentration of ISF Aβx–42 in barrel cortex (▪), piriform cortex (●),
hippocampus (○) and striatum (⋄ ) of 3.5 ± 0.5-month-old Tg2576 mice before the onset
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of plaque deposition (n = 5–8 per group; one-way ANOVA, Tukey's post hoc test for
multiple comparisons). (e,f) Steady-state concentrations of ISF Aβx–42 measured in each
brain region of young Tg2576 mice, plotted against subsequent Aβ (e) and amyloid (f)
plaque deposition in each brain region of aged Tg2576 mice. *P < 0.05; **P < 0.01;
***P < 0.001. Values represent mean ± s.e.m.
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Figure 3. Neuronal activity regulates ISF lactate concentration in vivo. (a)
Representative intraparenchymal EEG recordings from hippocampus of young Tg2576
mice during basal conditions, picrotoxin (PTX; 12.5 μM) treatment or tetrodotoxin (TTX;
5 μM) treatment by means of in vivo microdialysis (n = 4 per group). (b) Effect of local
PTX or TTX infusion on ISF lactate in hippocampus of young Tg2576 mice (n = 4 per
group; two-tailed t-test). (c) Effect of local PTX or TTX infusion on ISF Aβx–40 in
hippocampus of young Tg2576 mice (n = 4 per group; two-tailed t-test). Values in b,c
represent analyte concentrations during the final 6 h of drug treatment. (d) ISF lactate
concentrations were correlated with ISF Aβx–40 concentrations across treatment periods
(Pearson r = 0.7645; P < 0.0001). *P < 0.05; **P < 0.01. Values represent mean ± s.e.m.
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Figure 4. Steady-state ISF lactate levels in young Tg2576 mice are closely associated
with regional ISF Aβ levels in young Tg2576 mice and plaque deposition in aged
Tg2576 mice. (a–d) In vivo microdialysis measurements of steady-state ISF lactate
concentrations (expressed as a percentage of the striatal value) in barrel cortex (▪),
piriform cortex (●), hippocampus (○) and striatum (⋄ ) of young Tg2576 mice (n = 6–7
per group). ISF lactate concentration in each brain region is plotted against concentration
of ISF Aβx–40 (a) and ISF Aβx–42 (b) in each brain region of young Tg2576 mice. ISF
lactate concentration in each brain region of young Tg2576 mice is also plotted against
Aβ (c) and amyloid (d) plaque deposition in each brain region of aged Tg2576 mice.
Values represent mean ± s.e.m.
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Figure 5. Vibrissal activity regulates ISF Aβ levels in vivo. (a–c) Effect of vibrissal
deprivation on ISF Aβx–40 (a, black bars in c) and lactate (b, white bars in c)
concentrations relative to baseline (n = 6–7; two-tailed t-test). In vivo microdialysis was
performed in posterior barrel cortex of young Tg2576 mice. After establishing stable
basal ISF Aβx–40 and lactate concentrations, all vibrissae contralateral to the microdialysis
probe were trimmed to within 1 mm of the facial pad and microdialysis sample collection
continued for 16 h. (d) Effect of vibrissal stimulation on ISF Aβx–40 concentrations
compared to control conditions (n = 4; two-tailed t-test). In vivo microdialysis was
performed in barrel cortex in a separate cohort of young Tg2576 mice that underwent
subsequent unilateral vibrissal stimulation. Baseline Aβx–40 values were obtained for a 30min period. Unilateral mechanical stimulation of vibrissae contralateral to the
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microdialysis probe was performed for 30 min. *P < 0.05. Values represent mean ±
s.e.m.
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Figure 6. Diurnal fluctuation of ISF Aβ is closely associated with ISF lactate levels.
(a–c) In vivo microdialysis measurements from hippocampi of young Tg2576 mice
housed in 12 h light/12 h dark conditions. ISF Aβ1–x (a; black bars in c) and lactate (b;
white bars in c) concentrations were sampled throughout the light/dark cycle (n = 6; twotailed t-test). (d) ISF Aβ1–x concentrations plotted against ISF lactate concentrations
throughout the sleep/wake cycle (Pearson r = 0.6351; P < 0.0001). *P < 0.05; **P <
0.01. Values represent mean ± s.e.m.
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Figure 7. Vibrissal deprivation reduces amyloid plaque growth and formation in
vivo. (a,b) Representative multiphoton micrographs of individual amyloid plaques in
barrel cortex in control hemisphere of APP/PS1 mice before (a) and after (b) 28 d of
unilateral vibrissal deprivation. (c,d) Representative multiphoton micrographs of amyloid
plaques in barrel cortex in vibrissae-deprived hemisphere of APP/PS1 mice before (c)
and after (d) 28 d of vibrissal deprivation. (e,f) Quantification of mean plaque growth (e)
and new plaque formation (f) in vibrissae-deprived and control hemispheres (n = 6 mice;
two-tailed t-test). Arrows, existing amyloid plaques; arrowhead, newly formed amyloid
plaque. Scale bar, 50 μm; *P < 0.05; **P < 0.01. Values represent mean ± s.e.m.
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Supplementary Figure 1. Regional ISF Aβ and lactate levels in wild-type (B6SJL)
mice. (a) In vivo microdialysis was performed in hippocampus and striatum of 5.5 ± 0.5
month-old wild-type (B6SJL) mice. Murine ISF Aβx-40 levels were significantly greater
in hippocampus compared to striatum (n = 4 per group; two-tailed t-test). (b) Murine ISF
Aβx-40 levels were closely associated with ISF lactate levels in a region-specific manner
(n = 4). ◊, striatum; ○, hippocampus. **, P < 0.01. Values represent mean ± SEM.
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Supplementary Figure 2. Time course of picrotoxin and tetrodotoxin treatment on
ISF Aβx-40 and lactate levels in hippocampus. (a,b) Young (3.5 ± 0.5 month-old)
Tg2576 mice were treated sequentially with picrotoxin (12.5 μM; PTX) and tetrodotoxin
(5 μM; TTX) via reverse microdialysis during the microdialysis sampling period. (a) ISF
lactate and (b) Aβx-40 levels were increased during PTX treatment and decreased during
TTX treatment (n = 4 per group). Values represent mean ± SEM.
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Supplementary Figure 3. ISF Aβx-40 clearance rates across brain regions of young
Tg2576 mouse brain. (a,b) After baseline ISF Aβx-40 levels were established, young (3.5
± 0.5 month-old) Tg2576 mice were treated with a potent γ-secretase inhibitor,
Compound E (CPE; 10 mg kg–1), during the microdialysis sampling period to halt Aβ
synthesis and permit ISF Aβx-40 t1/2 determination. ISF Aβx-40 t1/2 did not differ across
barrel cortex (BC), hippocampus (HC) and striatum (ST; n = 4 per group; one-way
ANOVA, Tukey’s post hoc test for multiple comparisons). ○, barrel cortex; ■,
hippocampus; Δ, striatum. Values represent mean ± SEM.
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Supplementary Figure 4. APP expression and processing are not associated with
regional ISF Aβ levels or plaque deposition. (a–c) Piriform (PC), cingulate (CC) and
barrel (BC) cortices were dissected from fresh brain sections (500 μm thick) of young
(3.5 ± 0.5 month-old) Tg2576 mice. Dissected tissue samples were analyzed for
expression of (a) full-length APP, (b) CTF-β and CTF-α by western blot analysis. APP
and CTF expression in each lane was normalized to fluorescein-conjugated bovine serum
albumin (Fl-BSA) loading control. (c) Expression of APP, CTF-β and CTF-α did not
differ across piriform, cingulate and barrel cortices (n = 6 per group; one-way ANOVA,
Tukey’s post hoc test for multiple comparisons). (d–f) Whole cortex (CTX),
hippocampus (HC) and striatum (ST) were dissected from fresh brain tissue of young (3.5
± 0.5 month-old) Tg2576 mice. Dissected tissue samples were analyzed for expression of
(d) full-length APP, (e) CTF-β and CTF-α by western blot analysis. APP and CTF
expression in each lane was normalized to Fl-BSA loading control. (f) Expression of fulllength APP was significantly greater in cortex compared to hippocampus and striatum.
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CTF-β expression was greater in hippocampus compared to striatum. CTF-α expression
did not differ significantly across brain regions (n = 7 per group; one-way ANOVA,
Tukey’s post hoc test for multiple comparisons). ■, full-length APP; ■, CTF-β; □, CTF-α.
*, P < 0.05; **, P < 0.01. Panels a,b,d,e contain cropped blots. Values represent mean ±
SEM.
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Supplementary Figure 5. Glial activation in barrel cortex following long-term
vibrissae deprivation. (a) Low-power image of a representative brain section from an
APP/PS1 (7–7.5 months old) mouse that underwent 28-day unilateral vibrissae
deprivation stained with an anti-GFAP antibody to visualize astrocytes (green) and
counter-stained with X-34 to visualize amyloid plaque deposition (blue). No clear
difference in GFAP staining was evident between vibrissae-deprived (left; b) and control
(right; c) hemispheres (n = 6). (d) Low-power image of a representative brain section
from an APP/PS1 (7–7.5 months old) mouse that underwent 28 day unilateral vibrissae
deprivation stained with an anti-Iba-1 antibody to visualize microglia (red) and counterstained with X-34 to visualize amyloid plaque deposition (blue). No clear difference in
Iba-1staining was present between vibrissae-deprived (left; e) and control (right; f)
hemispheres (n = 6). White rectangles in a,d denote barrel cortex. Scale bars in a,d, 1
mm; scale bars in b,e, 50 μM.
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Chapter 4.
Bidirectional relationship between functional connectivity
and amyloid-β deposition in mouse brain

95

PREFACE
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ABSTRACT
Brain region-specific deposition of amyloid plaques principally composed of
extracellular aggregates of amyloid-β (Aβ) peptide is a pathological signature of
Alzheimer’s disease (AD). Recent human neuroimaging data suggest that resting-state
functional connectivity strength is reduced in patients with AD, cognitively normal
elderly harboring elevated amyloid burden, and in advanced aging. Interestingly, there
exists a striking spatial correlation between functional connectivity strength in
cognitively normal adults and the location of Aβ plaque deposition in AD. However,
technical limitations have heretofore precluded examination of the relationship between
functional connectivity, Aβ plaque deposition, and normal aging in mouse models. Using
a novel functional connectivity optical intrinsic signal (fcOIS) imaging technique, we
demonstrate that the magnitude of regional bilateral functional correlation in young
APP/PS1 mice prior to Aβ plaque formation was proportional to the amount of regionspecific plaque deposition seen later in older APP/PS1 mice. Furthermore, we found that
Aβ plaque deposition is associated with significantly reduced bilateral functional
connectivity in retrosplenial, frontal, cingulate, and motor cortices of older APP/PS1
transgenic mice. The degree of Aβ plaque deposition in each brain region was associated
with local bilateral functional connectivity decline. Normal aging was associated with
reduced bilateral functional connectivity specifically in retrosplenial cortex.

Together,

these findings suggest that the magnitude of local bilateral functional connectivity
predicts regional vulnerability to subsequent Aβ plaque deposition and that Aβ plaque
deposition and normal aging are associated with region-specific disruption of functional
connectivity in mouse brain.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia, characterized by
progressive structural and functional deterioration of higher-order neural networks. A
histopathological hallmark of AD is the presence of extracellular plaques primarily
composed of aggregated amyloid-β (Aβ) peptide. Under normal conditions, Aβ is
produced in neurons and is present in the extracellular space of the brain in soluble form
(Selkoe, 2001). During AD pathogenesis, soluble Aβ aggregates into Aβ oligomers and
insoluble extracellular amyloid plaques in a concentration-dependent manner (Yan et al.,
2009; Bero et al., 2011). In AD, amyloid plaque deposition is most prominent in the
default-mode network, a network of brain areas in which metabolism is preferentially
elevated during undirected mentation (Raichle et al., 2001; Buckner et al., 2005; Raichle
and Mintun, 2006; Vaishnavi et al., 2010; Vlassenko et al., 2010). Interestingly,
functional connectivity MRI (fcMRI) studies show that multiple regions of the defaultmode network exhibit high intrinsic functional connectivity in healthy brain (Hagmann et
al., 2008; Buckner et al., 2009). Moreover, recent data suggest that the relationship
between functional connectivity and AD is bidirectional, as functional connectivity is
disrupted in patients with AD (Supekar et al., 2008; Zhang et al., 2009), cognitively
normal elderly with elevated amyloid burden (Hedden et al., 2009; Sheline et al., 2010a;
Drzezga et al., 2011), and in advanced aging (Andrews-Hanna et al., 2007).
In mouse models of β-amyloidosis, Aβ plaque deposition is associated with
myriad neurotoxic effects, including neuritic dystrophy, impaired synaptic integration
and calcium dyshomeostasis (Knowles et al., 1999; D'Amore et al., 2003; Lombardo et
al., 2003; Tsai et al., 2004; Brendza et al., 2005; Garcia-Alloza et al., 2006; Kuchibhotla
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et al., 2008; Meyer-Luehmann et al., 2008; Kuchibhotla et al., 2009). However, because
technical limitations have precluded examination of systems-level functional connectivity
in model systems, the relationship between intrinsic functional connectivity, Aβ plaque
deposition and normal aging in mouse brain remains unclear. Given these limitations, we
designed a novel functional connectivity optical intrinsic signal (fcOIS) imaging
approach (White et al., 2011) wherein changes in reflected light intensity from the
surface of the brain are converted to changes in local hemoglobin concentration and used
to measure intrinsic functional connectivity. Herein, we utilize fcOIS to determine
whether the magnitude of regional bilateral functional connectivity prior to plaque
deposition is indicative of subsequent region-specific Aβ plaque deposition.
Additionally, we examine whether Aβ plaque deposition or normal aging is associated
with functional connectivity disruption in APPswe/PS1ΔE9 (APP/PS1) transgenic and
wild-type mice, respectively.
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MATERIALS AND METHODS
Animals. Male APPswe/PS1ΔE9 mice on a B6C3 background [APP/PS1(Jankowsky et
al., 2004)] and B6C3 wild-type mice (The Jackson Laboratory) were aged to 3.0 ± 0.5 or
11.5 ± 0.5 months of age for experimentation. Mice were given ab libitum access to food
and water. All experimental protocols were approved by the Animal Studies Committee
at Washington University.
Animal preparation.

In accord with our previously published animal preparation

protocol for fcOIS imaging (White et al., 2011), all mice were anesthetized with
ketamine-xylazine and allowed 15 minutes for anesthetic transition. In order to achieve a
equivalent depth of anesthesia across groups (as assessed by responsiveness to hind paw
pinch, anesthesia duration, respiratory rate, and heart rate), mice were administered the
following doses of 86.9 mg/kg ketamine, 13.4 mg/kg xylazine: 3 month-old APP/PS1,
1X; 11.5 month-old APP/PS1, 1.25X; all wild-type, 1.5X. Once induced, the animal was
placed on a heating pad maintained at 37°C via feedback from a rectal probe (mTCII,
Cell Microcontrols) and its head secured in a stereotactic frame using a nose cone and ear
bars. Scalp fur was shaved and cleaned, a midline incision was made along the top of the
head and the scalp was reflected, exposing approximately 1 cm2 of the skull. The skull of
each mouse was left intact and kept moist via application of mineral oil prior to the first
imaging session. Forty-five minutes of data were collected for 36 out of 37 imaging
sessions, with each imaging session consisting of consecutive five-minute data sets.
Anesthesia duration was approximately 70 minutes for all groups. Respiratory rate
during imaging sessions was monitored to be 3-4 Hz for all groups. Heart rate (measured
by Fourier analysis of the OIS time-courses collected from each mouse brain during
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imaging sessions) was similar across all groups (3 month-old APP/PS1, 3.3 ± 0.4 Hz;
11.5 month-old APP/PS1, 4.2 ± 0.3 Hz; 3 month-old wild-type, 3.9 ± 0.2 Hz; 11.5
month-old wild-type, 4.4 ± 0.3 Hz).
Imaging system. Sequential illumination was provided at four wavelengths by a ring of
light emitting diodes (LEDs) placed approximately 10 cm above the mouse's head.
Diffuse reflected light was detected by a cooled, frame-transfer EMCCD camera (iXon
897, Andor Technologies); the LED ring and the camera were time-synchronized and
controlled via computer using custom-written software (MATLAB, Mathworks) at a full
frame rate of 30 Hz. The secured mouse was placed at the focal plane of both the camera
and the LED ring and held in place with a stereotactic holder. The field-of-view was
adjusted to be approximately 1 cm2 square for each mouse resulting in images covering
the majority of the convexity of the cerebral cortex.
Image processing. Data from all mice were subject to an initial quality check prior to
spectroscopic analysis. Data runs (5 minutes) in which reflected light level intensity
(mean value over the brain) varied as a function of time by greater than 1% for any
wavelength were discarded and excluded from further analysis. This preliminary analysis
resulted in 15–45 minutes of data per mouse. For subsequent analysis, image light
intensity at each wavelength was interpreted using the Modified Beer-Lambert Law,
usually written as:
intensity,

0

(r,t) =

0*exp(-

a(r,t)*L).

is the baseline light intensity,

a(r,

Here,

(r,t) is the measured light

t) is the change in absorption

coefficient due to hemodynamic changes, and L is the optical path length factor for
photons in the tissue [calculated from Eqn. 34 as described (Arridge et al., 1992)]. As
there is no pre-stimulus baseline in resting-state experimentation, we instead normalized
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relative to the average light intensity at each pixel, resulting in differential measures of
absorption at each wavelength:

a,

(r,t) = -ln(

(r,t)/<

0

(r,t)>)/L . Absorption

coefficient data were converted to hemoglobin concentration changes by inverting the
system of equations,

a,

(r,t) = E

,i

[Hbi](r,t) (where E is the extinction coefficient

matrix (Prahl, 2002), and i runs over hemoglobin species). This inversion was performed
using least-squares methods, yielding changes in oxy- and deoxy-hemoglobin at each
pixel at each time point.
Since previous functional connectivity studies with diffuse optical tomography
(White et al., 2009) showed similar maps using either HbO2 or HbR contrast, here we
used only ΔHbO2 data for the connectivity analyses. Data were filtered to the functional
connectivity band (0.009-0.08 Hz) following previous human functional connectivity
algorithms (Fox et al., 2005). After filtering, each pixel's time series was resampled from
30 Hz to 1 Hz , and all further analysis was performed only on those pixels labeled as
brain. This procedure is necessary as every mouse's head is shaped differently, and the
view of the brain exposed varied slightly between surgeries. Time traces of all pixels
defined as brain were averaged to create a global brain signal. This global signal was
regressed from each pixel's time trace to remove global sources of variance, as is
common in human fMRI algorithms.
Seed-based functional connectivity measures. To investigate the strength of network
correlations, we focused on bilateral connectivity between homotopic areas in
contralateral hemispheres. Twelve seed locations were positioned at coordinates expected
to correspond to the left and right, frontal, cingulate, motor, somatosensory, retrosplenial
and visual cortices as described previously (White et al., 2011). Seed time-traces for the
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full data sets of each mouse (ranging from 15 to 45 minutes) were calculated by
averaging the time traces within 0.25 mm of the seed locus (containing approximately 30
pixels) of each seed location. Functional connectivity analysis was performed by
correlating these time courses against the time course of every pixel in the brain. This
procedure produces twelve functional connectivity maps over the mouse brain (one map
per seed). These functional connectivity maps were then compressed to a 12x12 seed-toseed correlation matrix by correlating each of the 12 seed time traces. Pearson r values
were converted to Fisher Z measures using: Z(r) = arctanh(r).
The above seed-to-seed correlation approach evaluates the functional connectivity
between only six regions of the brain. To further examine the bilateral connectivity across
the entire brain of each group of mice, 15 min of data were used from every mouse by
concatenating three randomly chosen, five-minute sequences out of a mouse's data set.
Each frame of the 15-minute image sequence (as well as the brain mask for that mouse)
was then affine-transformed to a common atlas space (Franklin and Paxinos, 1996)
determined by the positions of the junction between the coronal suture and sagittal suture
(posterior to the olfactory bulb and cerebrum along midline) and the position of lambda.
The stretch component for the anterior-posterior stretch was set equal to the mediallateral stretch. The intersection of the brain masks from all mice was calculated and made
symmetric by reflection across the midline allowing all subsequent comparisons across
mice to be performed only on brain areas shared between all mice.
To create the bilateral connectivity maps (Fig. 6), the 15-minute data sets from all
mice within a group were concatenated following transformation to create four larger
data sets. Every pixel was then used as a seed (which had a time trace consisting of the
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average of the 30 pixels around it as described above) and correlated against its
corresponding contralateral pixel, resulting in a symmetric map of correlation strengths
for each cohort.
Aβ plaque deposition. Animals were transcardially perfused with chilled phosphatebuffered saline (PBS, pH 7.4) with 0.3% heparin immediately following the final fcOIS
session. Brains were removed and postfixed in 4% paraformaldehyde at 4°C overnight.
Following fixation, brains were cryoprotected in 30% sucrose in PBS at 4°C for 72 hours.
Using a freezing sliding microtome (Microm), serial coronal sections (50-µm section
thickness) were collected from frontal cortex to caudal hippocampus. Sections (each
separated by 300 µm) were stained with biotinylated HJ3.4 (anti-Aβ1-13, mouse
monoclonal antibody generated in-house) to visualize Aβ immunopositive plaques.
Immunostained sections were scanned using a Nanozoomer slide scanner (Hamamatsu
Photonics). Quantitative analysis of percentage area covered by immunopositive staining
was performed as described previously (Kim et al., 2009b). Briefly, images of
immunostained sections were exported with NDP viewer (Hamamatsu Photonics),
converted to 8-bit grayscale using ACDSee Pro 2 software (ACD Systems), thresholded
to highlight Aβ-specific staining and analyzed using Image J software (National Institutes
of Health). A mouse brain atlas (Franklin and Paxinos, 1996) was used to identify
frontal, motor, somatosensory, cingulate, retrosplenial and visual cortices for quantitative
analysis of Aβ immunopositive staining.
Statistical analysis. Statistical significance was determined by two-tailed t-test if two
groups were compared. When variance differed significantly between groups, Welch’s ttest was used. One-way ANOVA followed by Tukey’s post hoc test for multiple
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comparisons were used when more than two groups were compared. All statistical
analyses were performed using Prism version 5.00 for Windows (GraphPad). Values
were accepted as significant if P < 0.05.
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RESULTS
Bilateral functional connectivity magnitude predicts region-specific Aβ plaque
deposition
In human brain, there exists a striking spatial correlation between areas of elevated
resting-state functional connectivity in cognitively normal adults and the topography of
Aβ plaque deposition in AD (Buckner et al., 2009). To examine the relationship between
intrinsic functional connectivity and Aβ plaque deposition in mouse brain, we utilized a
novel fcOIS imaging approach to characterize the magnitude of bilateral functional
connectivity in multiple brain systems of young (3.0 ± 0.5 months of age) APP/PS1 mice
prior to the onset of plaque deposition. Seed-based time traces of HbO2 concentration
in each region-of-interest were calculated and correlated with every pixel in the brain
(Fig. 1A-F). We found that the magnitude of bilateral functional correlation in young
APP/PS1 mouse brain was greatest in retrosplenial cortex (z(r), 1.4 ± 0.16), intermediate
in cingulate (0.96 ± 0.9), frontal (0.74 ± 0.06) and motor (0.99 ± 0.13) cortices, and low
in somatosensory (0.49 ± 0.06) and visual (0.6 ± 0.15) cortices (Fig. 1G; n = 7). A
similar pattern of regional functional connectivity magnitude was observed in agematched wild-type mice, suggesting that regional differences in bilateral functional
connectivity are intrinsic to normal brain physiology (n = 13; Fig. 2).
To determine whether regional bilateral functional connectivity magnitude in
young APP/PS1 mice prior to plaque deposition was indicative of the regional
vulnerability to Aβ plaque deposition in older APP/PS1 mice, we next characterized the
distribution of Aβ immunopositive plaque deposition in older (11.5 ± 0.5 months of age)
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APP/PS1 mouse brain. Brain sections were immunostained with biotinylated HJ3.4
antibody, to Aβ amino acids 1-13 (anti-Aβ1-13) to determine the percentage area occupied
by Aβ plaques in each region-of-interest (Fig. 3A-D). We found that Aβ plaque
deposition was greatest in retrosplenial cortex (18.01% ± 3.86), intermediate in cingulate
(9.04 ± 2.97), frontal (6.63 ± 1.63), motor (7.26 ± 1.38) cortices, and low in
somatosensory (3.74 ± 0.75) and visual (5.16 ± 0.69) cortices (Fig. 2E; n = 4). Bilateral
functional connectivity magnitude in young APP/PS1 mice prior to plaque deposition
was thus proportional to the amount of Aβ plaque deposition in older APP/PS1 mice in a
region-specific manner (Fig. 3F).
Aβ plaque deposition and normal aging are associated with functional connectivity
disruption
Amyloid plaque deposition is associated with reduced resting-state functional
connectivity in patients with AD (Supekar et al., 2008; Zhang et al., 2009) and
cognitively normal adults who harbor significant amyloid load (Hedden et al., 2009;
Sheline et al., 2010a; Drzezga et al., 2011). Therefore, we utilized fcOIS to determine
whether Aβ plaque deposition was associated with decreased functional connectivity in
older (11.5 ±0.5 months of age) APP/PS1 mice. Relative to 3 month old APP/PS1 mice,
11.5 month old APP/PS1 mice exhibited significant reductions in bilateral functional
correlation strength in frontal (z(r), 0.49 ±0.08; P = 0.0298), motor (0.48 ± 0.15; P =
0.0217), cingulate (0.58 ± 0.13; P = 0.0312) and retrosplenial (0.46 ± 0.06; P = 0.0009)
cortices. No significant differences were observed in somatosensory (0.32 ± 0.12; P =
0.2266) or visual (0.21 ± 0.1; P = 0.0571) cortices (Fig. 4A-G; n = 7).
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In humans, normal aging is associated with disruption of functional connectivity in
multiple brain areas (Andrews-Hanna et al., 2007). We thus sought to determine whether
normal aging was associated with reduced bilateral connectivity in older (11.5 ± 0.5
months old) B6C3 wild-type mice. Compared to young B6C3 wild-type mice, 11.5
month old wild-type mice exhibited a significant reduction in bilateral connectivity in
retrosplenial cortex (z(r), young, 1.1 ± 0.06; 11.5 month, 0.69 ± 0.07; P = 0.0002). In
contrast, comparisons of bilateral functional connectivity between young and 11.5 month
old wild-type mice were not significant in frontal (young, 0.81 ± 0.1; 11.5 month, 0.71 ±
0.09; P = 0.4554), motor (young, 0.68 ± 0.07; 11.5 month, 0.83 ± 0.14; P = 0.2954),
somatosensory (young, 0.45 ± 0.11; 11.5 month, 0.67 ± 0.08; P = 0.1438), cingulate
(young, 0.99 ± 0.09; 11.5 month, 1.0 ± 0.09; P = 0.9370) or visual (young, 0.42 ± 0.08;
11.5 month, 0.52 ± 0.1; P = 0.4383) cortex (Fig. 5A-G; n = 10–13/group).
To more closely examine the spatial relationship between Aβ plaque deposition and
age-related decline in bilateral functional connectivity in APP/PS1 mice, an equal number
of fcOIS data sets from each mouse were affine-transformed to a common atlas space and
concatenated before calculating the correlation between each bilateral pixel set in the
brain. Thus, a single full-field consensus bilateral connectivity map was generated for
each cohort (Fig. 6A,B,D,E). Notably, the consensus bilateral connectivity maps
generated for each cohort qualitatively reproduce the regional differences in bilateral
functional connectivity magnitude reported above. To examine pixel-wise, age-related
changes in bilateral functional connectivity magnitude, bilateral correlation consensus
values generated from older mice were subtracted from bilateral correlation consensus
values generated from young mice of the same genotype. The resultant difference maps
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reveal regional differences in the level of age-related functional decline in APP/PS1 (Fig.
6C) and wild-type (Fig. 6F) mice. In APP/PS1 mice, age-related decline in functional
connectivity was greatest in retrosplenial cortex and lowest in somatosensory cortex (Fig.
6C). As the level of plaque deposition in older APP/PS1 mice was greatest in
retrosplenial cortex and lowest in somatosensory cortex, this finding suggests that the
amount of regional plaque deposition is linked with the level of age-related decline in
local bilateral functional connectivity. In wild-type mice, retrosplenial cortex exhibited
the greatest age-related decline in functional connectivity while subtle increases in
bilateral functional correlation were observed in motor and somatosensory cortices (Fig.
6F). Together, these data suggest that bilateral functional connectivity in mouse brain is
reduced in normal aging and is markedly exacerbated by Aβ accumulation in the brain in
a region-specific pattern.
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DISCUSSION
In human brain, there exists a striking spatial correlation between areas that exhibit
disproportionately high resting-state functional connectivity in cognitively normal adults
and the distribution of amyloid plaque deposition in AD (Buckner et al., 2009).
Moreover, functional connectivity is decreased in AD and cognitively normal individuals
who harbor elevated amyloid deposition (Supekar et al., 2008; Hedden et al., 2009;
Zhang et al., 2009; Sheline et al., 2010a; Drzezga et al., 2011). Thus, elucidating the
mechanisms that underlie the relationship between functional connectivity and Aβ plaque
deposition may inform AD pathobiology and potentially reveal novel therapeutic
avenues. However, as the small size of mouse brain necessitates an exceptionally high
signal-to-noise ratio to achieve sufficient spatial resolution for functional magnetic
resonance imaging, the relationship between functional connectivity and Aβ plaque
deposition in mouse brain has remained unknown. Here, we utilize a novel fcOIS
imaging approach (White et al., 2011) to characterize the relationship between functional
connectivity, Aβ plaque deposition, and normal aging in mouse brain. We found that
bilateral functional connectivity magnitude varied significantly across brain regions of
young APP/PS1 mice and that the magnitude of region-specific bilateral functional
correlation in young APP/PS1 mice prior to the onset of Aβ plaque formation was
proportional to the density of regional plaque deposition in older APP/PS1 mice. This
finding is consistent with human data suggesting that heteromodal association areas of
the default-mode network exhibit disproportionately high intrinsic structural and
functional connectivity in cognitively normal young adults and are among the brain
regions most vulnerable to Aβ deposition in AD (Hagmann et al., 2008; Buckner et al.,
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2009). Importantly, as shown here, this OIS imaging approach combined with mouse
models of neurodegeneration should allow for novel insights with regard to the role of
specific genes/proteins in systems-level neural function.
Several reports have demonstrated that functional connectivity is impaired in AD and
in cognitively normal elderly harboring significant amyloid plaque burden (Supekar et
al., 2008; Hedden et al., 2009; Zhang et al., 2009; Sheline et al., 2010a; Drzezga et al.,
2011). In accord with these human data, the present findings suggest that region-specific
Aβ accumulation is associated with significant reductions in bilateral functional
connectivity magnitude in multiple brain systems of older APP/PS1 mice. Moreover, we
observed that brain regions in which amyloid deposition was most prominent (e.g.
retrosplenial cortex) exhibited greater age-related declines in functional connectivity
relative to areas of lesser plaque deposition (e.g. somatosensory cortex). As Aβ plaque
deposition is associated with local neuritic dystrophy and impaired synaptic integration in
APP transgenic mice (Knowles et al., 1999; D'Amore et al., 2003; Lombardo et al., 2003;
Tsai et al., 2004; Brendza et al., 2005; Garcia-Alloza et al., 2006; Meyer-Luehmann et
al., 2008) future application of fcOIS will permit examination of the molecular
mechanisms that underlie the relationship between Aβ plaque deposition and impaired
systems-level functional connectivity.
In humans, normal age-related memory deficits are associated with decreased
functional correlation between medial prefrontal cortex and posterior
cingulate/retrosplenial cortex (Andrews-Hanna et al., 2007). Here, we found that
retrosplenial cortex exhibits decreased bilateral functional connectivity in wild-type mice
at 11.5 months of age. As age-related memory deficits are not present in wild-type mice
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at this age, and given that retrosplenial cortex is important for learning and memory
(Keene and Bucci, 2008, 2009; Corcoran et al., 2011), impaired bilateral functional
connectivity in retrosplenial cortex may represent an early event in age-related neural
dysfunction that ultimately results in memory impairment. In this context, fcOIS may
serve as a useful tool to investigate the molecular mechanisms that contribute to
decreased functional connectivity and memory dysfunction associated with normal aging.
Our laboratory has recently demonstrated that regional differences in endogenous
neuronal activity are closely associated with interstitial fluid Aβ levels and are a key
determinant of region-specific Aβ plaque deposition in APP transgenic mice (Bero et al.,
2011). As the present data suggest that regional bilateral functional connectivity
magnitude in young mice prior to plaque deposition is also associated with the level of
subsequent Aβ plaque deposition, it will be important to examine the relationship
between neuronal population activity and systems-level functional connectivity and how
these mechanisms may independently or coordinately regulate Aβ metabolism.
A major challenge facing the neuroscience community is the paucity of clinically
translatable assays that examine neural network function and integrity. Given that
resting-state functional connectivity measures have provided valuable information
regarding the functional organization of human brain (Fox and Raichle, 2007) and have
yielded examples of how such organization is disrupted in disease (Zhang and Raichle,
2010), use of fcOIS in combination with genetic and molecular manipulations in mouse
models provides an translational opportunity to elucidate mechanisms that underlie
intrinsic functional connectivity in healthy brain and its disruption in models of
neurological and neurodegenerative disorders. The clinically translatable nature of fcOIS
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also positions this technique as a useful tool with which to examine the efficacy of
pharmacological or behavioral interventions aimed to restore neural network integrity in
such mouse models.
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Figure 1. fcOIS reveals regional differences in bilateral functional connectivity
magnitude in APP/PS1 mice prior to Aβ plaque deposition. A-F, Representative seedbased functional correlation maps of frontal (FC; A), motor (MC; B), somatosensory (SC;
C), cingulate (CC; D), retrosplenial (RC; E) and visual (VC; F) cortices in 3.0 ± 0.5
month-old APP/PS1 mice. Black circles denote seed position and size. Scale, Pearson r
= -1 to 1. G, Fisher z-transformed correlation values of bilateral functional correlation
magnitude in each region of interest (n = 7/group). *, P < 0.05; **, P < 0.01; ***, P <
0.001 (one-way analysis of variance (ANOVA), Tukey’s post hoc test for multiple
comparisons). Values represent mean ± s.e.m.
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Figure 2. fcOIS reveals regional differences in bilateral functional connectivity
magnitude in young wild-type mice. A-F, Representative seed-based functional
correlation maps of frontal (FC; A), motor (MC; B), somatosensory (SC; C), cingulate
(CC; D), retrosplenial (RC; E) and visual (VC; F) cortices in 3.0 ± 0.5 month-old wildtype mice. Black circles denote seed position and size. Scale, Pearson r = -1 to 1. G,
Fisher z-transformed correlation values of bilateral functional correlation magnitude in
each region of interest (n = 13/group). *, P < 0.05; ***, P < 0.001 (one-way analysis of
variance (ANOVA), Tukey’s post hoc test for multiple comparisons). Values represent
mean ± s.e.m.
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Figure 3. Regional bilateral functional connectivity magnitude in young APP/PS1
mice is closely associated with regional plaque load in older APP/PS1 mice. A-D,
Representative brain sections from aged (11.5 ± 0.5 month-old) APP/PS1 mice stained
with biotinylated HJ3.4 antibody (anti-Aβ1-13) to visualize Aβ immunopositive plaques.
Scale bar, 500 µm. E, Percentage area occupied by Aβ deposition in frontal (FC), motor
(MC), somatosensory (SC), cingulate (CC), retrosplenial (RC) and visual (VC) cortices
(n = 4 per group). F, Fisher z-transformed correlation values of bilateral functional
correlation magnitude in frontal (▲), motor (Δ), somatosensory (■), cingulate (○),
retrosplenial (●) and visual (□) cortex of young APP/PS1 mice, plotted against
subsequent Aβ plaque deposition in each brain region of aged APP/PS1 mice. *, P <
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0.05; **, P < 0.01 (one-way ANOVA, Tukey’s post hoc test for multiple comparisons).
Values represent mean ± s.e.m.
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Figure 4. Aβ plaque deposition is associated with decreased functional connectivity
magnitude in multiple brain systems of older APP/PS1 mice. A-F, Representative
seed-based functional correlation maps of frontal (FC; A), motor (MC; B), somatosensory
(SC; C), cingulate (CC; D), retrosplenial (RC; E) and visual (VC; F) cortices in 11.5 ±
0.5 month-old APP/PS1 mice. Black circles denote seed position and size. Scale,
Pearson r = -1 to 1. G, Fisher z-transformed correlation values of bilateral functional
correlation magnitude in each region of interest in young (black bars) and older (white
bars) APP/PS1 mice (n = 7/group). *, P < 0.05; ***, P < 0.001 (one-way ANOVA,
Tukey’s post hoc test for multiple comparisons). Values represent mean ± s.e.m.
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Figure 5. Normal aging is associated with decreased functional connectivity
magnitude in retrosplenial cortex. A-F, Representative seed-based functional
correlation maps of frontal (FC; A), motor (MC; B), somatosensory (SC; C), cingulate
(CC; D), retrosplenial (RC; E) and visual (VC; F) cortices in 11.5 ± 0.5 month-old wildtype mice. Black circles denote seed position and size. Scale, Pearson r = -1 to 1. G,
Fisher z-transformed correlation values of bilateral functional correlation magnitude in
each region of interest in young (black bars) and older (white bars) wild-type mice (n =
10–13/group). ***, P < 0.001 (one-way ANOVA, Tukey’s post hoc test for multiple
comparisons). Values represent mean ± s.e.m.

119

Figure 6. Regional Aβ plaque deposition is associated with degree of age-related
decline in bilateral functional connectivity. A,B, Consensus bilateral functional
connectivity maps generated for young (A) and older (B) APP/PS1 mice. C, Difference
map reveals region-specific, age-related decline in bilateral functional connectivity
magnitude in APP/PS1 mice. D,E, Consensus bilateral functional connectivity maps
generated for young (D) and older (E) wild-type mice. F, Difference map reveals regionspecific, age-related decline in bilateral functional connectivity magnitude in wild-type
mice. Scale in A,B,D,E, Fisher z = -1.4 to 1.4. Note that in C,F, positive values represent
age-related decline, while negative values represent age-related increase, in bilateral
functional connectivity magnitude.
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Chapter 5.
Conclusions and future directions
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Summary
As amyloid plaque deposition is a necessary event in AD pathogenesis, we sought
to elucidate the factors that regulate cerebral amyloid plaque growth in vivo (Chapter 2 of
this dissertation). Using intravital multiphoton microscopy through a thinned-skull
cranial window in APP/PS1 bitransgenic mice, we found that amyloid plaques present in
cortex of 6 month-old APP/PS1 mice exhibited significant growth over a period of
weeks, while significant amyloid plaque growth was not present in 10 month-old
APP/PS1 mice. In contrast, plaques imaged through an open-skull cranial window did
not exhibit significant growth at either age, likely due to increased cortical gliosis in
open-skull window preparations. Under thinned-skull window preparations, plaque
growth rate was inversely proportional to initial plaque size in 6 and 10 month-old mice.
Amyloid plaque formation and growth were prevented by pharmacological γ-secretase
inhibition. In vivo microdialysis experiments performed in young APP/PS1 mice showed
that reduction of ISF Aβ levels by 20-25% over the course of 24 hours was associated
with a dramatic reduction in amyloid plaque formation and growth. Together, these data
suggest that amyloid plaque formation and growth in vivo occurs over weeks and is
closely related to animal age, initial plaque size and ISF Aβ concentration.
Though region-specific deposition of Aβ plaques is a fundamental feature of AD,
the mechanisms that regulate the regional vulnerability to Aβ plaque deposition in AD
remain unknown. We sought to address this issue in Chapter 3 of this dissertation. Using
in vivo microdialysis, we found that the steady-state concentrations of ISF Aβx-40 and Aβx42 in

young Tg2576 mice prior to the onset of plaque deposition were closely associated

with the spatial distribution of Aβ deposition in aged mice. We found that ISF lactate
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level was a valid marker of neuronal activity in vivo and that regional ISF lactate levels in
young Tg2576 mice were closely associated with regional ISF Aβ levels and subsequent
region-specific Aβ and amyloid plaque deposition. We found that region-specific Aβ
plaque deposition was not predicted by ISF Aβ clearance rate, full-length APP expression
or APP processing. To determine whether physiological neuronal activity directly
regulates ISF Aβ levels, we used in vivo microdialysis to determine the effect of
unilateral vibrissal trimming or stimulation on ISF Aβ levels in contralateral barrel cortex
of young Tg2576 mice. We found that unilateral vibrissal trimming acutely reduced, and
unilateral vibrissal stimulation acutely increased, ISF Aβ levels in contralateral barrel
cortex. Using multiphoton microscopy, we found that long-term unilateral vibrissal
trimming significantly reduced amyloid plaque formation and growth in contralateral
barrel cortex. The results presented in Chapter 3 thus suggest that regional differences in
steady-state neuronal activity regulate region-specific Aβ plaque deposition through longterm modulation of ISF Aβ concentration.
In Chapter 4, we sought to examine the relationship between functional
connectivity, Aβ plaque deposition and normal aging in mouse brain. As technical
limitations have heretofore precluded examination of systems-level functional
connectivity in mouse brain, we utilized a novel fcOIS technique (White et al., 2011) to
conduct the first study of systems-level functional connectivity in a mouse model of
neuropathology or normal aging. We found that regional differences in bilateral
functional connectivity magnitude were present in young APP/PS1 and wild-type mice.
Interestingly, bilateral functional connectivity magnitude in young APP/PS1 mice was
proportional to region-specific Aβ plaque deposition in aged APP/PS1 mice. The
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relationship between functional connectivity and Aβ plaque deposition appeared to be
bidirectional, as we found that Aβ deposition was associated with marked reductions in
bilateral functional connectivity magnitude in several brain systems of aged APP/PS1
mice. In wild-type mice, normal aging was associated with a specific decrease in
bilateral functional connectivity in retrosplenial cortex. Finally, we found that the degree
of regional functional connectivity decline in aged APP/PS1 mouse brain was associated
with the amount of region-specific Aβ plaque deposition. These data suggest a close
relationship between functional connectivity, Aβ deposition and normal aging in mouse
brain and provide a foundation for future investigation of the molecular mechanisms that
underlie systems-level neural network dysfunction.

124

Super-resolution examination of AD pathogenesis
Since the seminal work of Santiago Ramón y Cajal, microscopic analysis of brain
tissue has yielded fundamental insights into brain structure, function and the mechanisms
by which pathological insults disrupt neural integrity. Until recently however, the
diffraction limit of light has prevented molecular-level visualization of specific
biomolecules in tissue sections. The advent of super-resolution fluorescence microscopy
techniques such as stochastic optical reconstruction microscopy (STORM) now permits
nanometer level examination of specific molecules in biological samples (Dani and
Huang, 2010; Dani et al., 2010).
In Chapter 3 of this dissertation, we found that regional differences in steady-state
neuronal activity regulate brain region-specific ISF Aβ levels and amyloid plaque growth
dynamics in vivo. However, the mechanisms that regulate intrinsic differences in
regional neuronal activity remain unclear. As synaptic vesicle exocytosis is necessary for
neuronal activity-dependent Aβ secretion (Cirrito et al., 2005), molecular-level
examination of synaptic protein expression across brain regions may provide valuable
insights into the mechanisms that regulate region-specific Aβ plaque deposition. To this
end, we have begun to use STORM to quantify markers of synapse density and
neurotransmitter receptor composition (including GluR1, GluR1-Ser831-P, NR2A and
CamKII-P) across cortical regions that exhibit differential susceptibility to Aβ plaque
deposition. We hypothesize that synapse density and neurotransmitter receptor
expression density in each brain region of young APP transgenic mice prior to the onset
of plaque deposition will be proportional to the amount of region-specific Aβ plaque
deposition in aged APP transgenic mice. Our in vivo microdialysis data suggest that
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regional differences in neuronal activity present in young APP transgenic mice are
similar to those present in wild-type mice (Chapter 3 of this dissertation). Using
STORM, we will also examine synapse density and neurotransmitter receptor expression
across brain regions of young wild-type mice to determine whether regional differences
in synaptic architecture present in young APP transgenic mice are intrinsic to normal
brain physiology or are affected by overproduction of full-length APP or APP cleavage
derivatives such as Aβ.
It is well-established that Aβ plaque deposition is associated with synaptic loss in
AD brain (Terry et al., 1991; Coleman and Yao, 2003) and mouse models of Aβ
deposition (Koffie et al., 2009). However, technical limitations have heretofore
precluded molecular-level examination of the effect of Aβ deposition on synaptic
architecture in intact tissue. Therefore it will be of interest to use STORM to image
synaptic protein expression in brain sections from aged APP transgenic mice that harbor
Aβ plaque deposition and age-matched wild-type controls to examine whether Aβ
deposition is associated with reduced local synapse density and neurotransmitter receptor
expression. Anti-Aβ immunotherapy has been shown to prevent and remove cerebral Aβ
deposition in APP transgenic mice (Schenk et al., 1999; Bard et al., 2000; Wilcock et al.,
2004; Brody and Holtzman, 2008). Therefore, if Aβ plaque deposition is found to be
associated with local reductions in synapse density and neurotransmitter receptor
expression, a potential follow-up experiment would be to determine whether systemic
anti-Aβ immunotherapy can prevent or reverse synaptic disruption in aged APP
transgenic mice.
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Moreover, STORM could be used to determine whether regional differences in
the level of synaptic structural disruption are present in aged APP transgenic mice. If
regional differences in synaptic disruption are present in aged APP transgenic mice, this
result would provide an opportunity to link molecular-level structural disruption with
systems-level functional dysfunction by examining whether the degree of molecular-level
synaptic structural disruption in each brain region assessed by STORM is proportional to
the degree of bilateral functional connectivity disruption in aged APP transgenic mice
assessed by fcOIS.
Mechanisms of functional connectivity disruption in AD
Using a novel fcOIS approach, we found that Aβ plaque deposition is closely
associated with region-specific functional connectivity decline in APP/PS1 mouse brain
(Chapter 4 of this dissertation). As the experiments described in Chapter 4 were designed
to determine whether Aβ plaque deposition was spatially correlated with decreased
functional connectivity magnitude, whether Aβ aggregation is directly responsible for the
observed functional connectivity decline in aged APP/PS1 mice remains unclear.
Therefore, we have begun experiments to test whether systemic passive anti-Aβ
immunotherapy in Tg2576 mice prior to the onset of robust plaque deposition prevents
functional connectivity decline relative to vehicle-treated, age-matched Tg2576 mice.
Since systemic anti-Aβ immunotherapy has also been suggested to clear existing Aβ
plaques from the brain, one potential follow-up experiment would be to begin anti-Aβ
immunotherapy in Tg2576 mice that harbor robust plaque deposition to determine
whether Aβ plaque removal rescues functional connectivity dysfunction once significant
Aβ plaque deposition has occurred.
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Since AD is characterized by the presence of multiple neuropathological
hallmarks, including amyloid plaque deposition, tau hyperphosphorylation and
neurofibrillary tangle formation, one limitation of functional neuroimaging experiments
in AD patients is the inability to attribute functional deficits to specific components of the
disease process. However, given that we have recently utilized fcOIS to perform the first
systems-level functional connectivity experiments in a mouse model of neuropathology
(Chapter 4 of this dissertation), it is now possible to examine neural network function in
transgenic mice that model specific neuropathological components of the AD process. In
this context, it would be of interest to utilize fcOIS to examine whether tau
hyperphosphorylation or neurofibrillary tangle formation is associated with decreased
functional connectivity magnitude in a transgenic mouse model of tauopathy such as
P301S (Yoshiyama et al., 2007). Although a comprehensive examination of regional
differences in tau hyperphosphorylation and intracellular inclusion formation in P301S
mice has not yet been performed, available data suggest that this model harbors relatively
severe tau pathology in hippocampus and select cortical regions. Given the dense
projections of hippocampus to retrosplenial cortex (Wyss and Van Groen, 1992), bilateral
functional connectivity magnitude may be particularly decreased in retrosplenial cortex
of P301S mice. Data suggest that tau immunotherapy can reduce tau
hyperphosphorylation and aggregation in a mouse model of tauopathy (Boutajangout et
al., 2010). Thus, if tau hyperphosphorylation and neurofibrillary tangle formation are
shown to be associated with decreased functional connectivity magnitude, it would be
interesting to determine whether tau immunotherapy can prevent or reverse functional
connectivity dysfunction in mouse models of tauopathy.
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Differential regulation of Aβ clearance is widely hypothesized to represent a
principle mechanism by which apoE isoforms differentially modulate susceptibility to
AD (Castellano et al., 2011). Interestingly, human functional neuroimaging data suggest
that resting-state and task-induce brain activation are upregulated in ε4 carriers relative to
non-carriers prior to and following cerebral amyloid deposition (Bookheimer et al., 2000;
Filippini et al., 2009). Moreover, functional connectivity abnormalities have been
reported in cognitively normal ε4 carriers relative to noncarriers (Fleisher et al., 2009;
Sheline et al., 2010b; Machulda et al., 2011) and human ε4 knock-in mice exhibit
reduced excitatory synaptic transmission and reduced dendritic spine density in certain
brain regions (Wang et al., 2005) . Therefore, altered brain activity and functional
connectivity may represent an additional mechanism by which ε4 modulates AD risk. In
this context, it would be of interest to utilize fcOIS to determine whether human ε2, ε3 or
ε4 knock-in mice exhibit differential functional connectivity magnitude in the absence of
Aβ pathology and whether normal age-related changes in functional connectivity
magnitude are altered in an isoform-dependent manner. Moreover, using APP transgenic
mice crossed with human ε2, ε3 or ε4 knock-in mice (Bales et al., 2009), it would be
interesting to determine whether apoE isoform-dependent differences in steady-state ISF
Aβ levels present throughout life and resultant differences in Aβ plaque deposition in
aged mice (Castellano et al., 2011) are associated with differential functional connectivity
magnitude.
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Concluding remarks
Brain region-specific deposition of extracellular Aβ plaques is a pathological
hallmark of AD. However, the mechanisms that regulate the regional vulnerability to Aβ
plaque deposition in AD remain unknown. In this thesis, we utilized mouse models of
cerebral Aβ deposition to examine molecular, cellular and systems-level mechanisms that
regulate brain region-specific Aβ accumulation and aggregation. We found that amyloid
plaque formation and growth is closely related to ISF Aβ concentration and that local
steady-state neuronal activity levels regulate region-specific ISF Aβ levels and Aβ plaque
deposition in vivo. Using a novel fcOIS technique, we also provide the first examination
of systems-level functional connectivity in a mouse model of neuropathology or normal
aging. We found that regional bilateral functional connectivity magnitude in young mice
prior to the onset of Aβ deposition was proportional to the amount of region-specific Aβ
deposition in aged mice. Moreover, we found that normal aging, and to a greater extent,
Aβ deposition, were associated with marked decreases in bilateral functional
connectivity. Together, these findings advance our understanding of the mechanisms by
which specific brain regions are rendered vulnerable to Aβ plaque deposition in AD and
suggest that intrinsic brain metabolism and functional organization may contribute to AD
pathogenesis.
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